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Abstract
Acquired Immunodeficiency Syndrome (AIDS) is an ailment like no other. Despite huge
improvements in treatments for the Human Immunodeficiency Virus (HIV), which causes AIDS,
those living with the disease continue to suffer from treatment inequality and discrimination.
This is especially true in the European Union (EU), which is a supranational entity that works to
improve prosperity, equality, and wellbeing among member-states. Despite extensive EU efforts
to improve the standard of living across the inter-governmental body, treatment inequality for
those living with HIV/AIDS in the EU continues to be a major issue. This study hypothesized
that a strong EU initiative, which would establish a European Healthcare System with firm
treatment guidelines, would reduce inequality and work to improve the lives of those living with
HIV/AIDS in the EU. This study was divided into several parts, which analyzed the procedural
characteristics of the British, German, and Italian healthcare systems, as well as that of the
existing healthcare policies and initiatives in the EU. Each of the preceding cases were EU
countries that have significantly different treatment experiences for HIV/AIDS patients
compared to the EU average. Additional case studies were also conducted to analyze the legal
and social frameworks affecting this disease in each case. Results of this investigation indicated
that a common EU-healthcare policy might ultimately be effective in improving treatment
equality across the continent. However, it was also shown that current financial troubles
affecting member-states, coupled with waning public support for the EU, would create divides in
the European community, and a supranational healthcare policy would likely be counterproductive to improving patient’s lives.
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Introduction
Europe has united to become one of the greatest examples of peace and prosperity on the
planet. Much of this continent’s history is riddled with conflict, inequality, and periods of
authoritarianism; yet, the Europe that we see today is a leading example of how peace between
the greatest of rivals can be achieved. In the 1930s the idea of any sort of friendship existing
between nations like France and Germany seemed ludicrous. Less than a century later, these two
countries are not only firm partners, but share open borders and a common currency. Such great
improvements in European cooperation and stability have flourished in many areas, most notably
in terms of the economy, but this has not been true for certain other functions of government.
European integration has been extremely successful at creating a strong, unified, and efficient
system of supranational governance that has harmonized regional differences and helped to make
the European Union (EU) one the most prosperous areas in the world in terms of combined GDP
(Gross Domestic Product). European integration has come substantially far, but policy areas such
as healthcare have seen comparatively little integration, resulting in varying standards and
quality of care, which is something not at all consistent with the idea of a modern, equal, and fair
Europe. Treatment experiences for HIV/AIDS and other chronic diseases are quite different
across nations, and a common European Union (EU) healthcare policy should help to improve
overall healthcare efficiency as well as treatment across the continent, in the same way that a
common EU policy has developed an effective multinational European approach to other policy
issues.
One of the better examples of a strong coordinated, and multi-national European policy is
that of the Schengen agreement. This treaty sets up clearly defined rules and procedures for open
borders and freedom of movement across the continent. Whenever situations with respect to
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border issues arise in the European Union, the Schengen agreement can be referenced as the
ground law. The same cannot be said for other policy areas, particularly healthcare. Despite all of
the improvements we have seen throughout the past century; in today’s Europe, healthcare is still
very inconsistent across countries. Even though cooperation among European nations is arguably
greater now than it has ever been; costs, treatment effectiveness, healthcare procedures, and
access to basic care vary greatly across the EU.
After having looked at a number of European healthcare systems, three particularly
strong cases come to mind. The first is the United Kingdom, a nation with a typical system of
universal health coverage that is at the forefront of European politics. Italy is another important
case to examine, because while this nation has a similar universal healthcare system to that of the
United Kingdom, it faces unique geographic, economic, and political challenges not experienced
by most other EU member-states. Germany is another prominent case that is of particular interest
due to the fact that it does not have a classic system of universal healthcare, but instead has a
complex system of public and private insurance providers that define its health services. The
healthcare system in every European nation is unique, yet every one of these healthcare systems
contains aspects found in other countries.
Performing an in-depth examination of the healthcare system in each individual nation in
the European Union would allow for a comparison that would hopefully point to a member-state
that excels at healthcare compared to other countries, and whose healthcare model could be
exported to the rest of the EU. However, measuring healthcare practices and efficiency must also
include cultural and economic variables, which play a huge role in defining how a healthcare
system actually works in practice. It is also true that the governments, policies, and thus
healthcare systems tend to overlap among different European nations. For instance, nations like
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Sweden and Denmark may each have their own unique systems of healthcare, yet elements of
one will be found in the other. This is also the case for healthcare systems that are generally
thought of as being procedurally different, such as those of the United Kingdom and Germany.
Performing a qualitative study of the healthcare systems, as well as all of the related explanatory
variables in each member-state of the European Union would be impractical considering the time
such a study would take and the relative similarities among EU member-states. Therefore,
examining three of the largest, most prominent, and developed healthcare systems on the
continent will allow for a time and resource efficient qualitative study to be conducted. From the
results of those cases, it is my belief that an optimal system of healthcare may be found. Optimal
in this sense means cost and treatment effective, as well as being “exportable,” or having the
capacity to be integrated across member-states of the European Union.
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Literature Review
Using HIV/AIDS to study different healthcare systems in Europe requires several
important elements of background research. The first is an examination of differences among
individual healthcare systems in Europe and around the world, followed by a look at what sort of
research has been conducted with respect to why such variations exist among these nations. The
second is to look at studies conducted on treatment experiences for HIV/AIDS in Europe and the
world, which will allow me to get a sense of what type of research has been done in terms of
cultural and nationalistic factors affecting treatment. Lastly, theories of European integration
should be analyzed to get a sense of what steps the European Union as a whole may take in the
future with respect to healthcare.
Comparison of Healthcare Systems
Europe with Respect to the World
Healthcare policy is not standard across European nations or elsewhere. Even for
countries that are members of the European Union, the differences between healthcare policies
are vast. Experts Kieke Okma and Theodore Marmor point out in a 2013 cross-sectional study
that differences in global healthcare systems are immense. Even among first world countries
“there is a lack of generally agreed [medical] vocabulary” (Okma and Marmor, 487, 2013).
These authors also point out that such differences lead to “misleading terms,” which in part
defines the large differences in healthcare systems that we see (Okma and Marmor, 487, 2013).
The bulk of Okma and Marmor’s research compared the American, Canadian, and European
healthcare systems. One of the chief differences that were pointed out is that Europeans consider
terms like “primary care” things that keep “patients out of the hospital,” while in nations like
Canada “primary care connotes community involvement” (Okma and Marmor, 488, 2013). Such
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differences imply a large variance in healthcare services. Okma and Marmor’s comments on the
Canadian healthcare system, as well as that of other nations, imply that home-based healthcare
services, and early detection of disease are generally the first healthcare initiatives of European
countries.
Other researchers have created more concrete models, which they believe global
healthcare systems fall into. Authors Ashish Chandra, William Willis, and Katherine Miller
analyzed several particularly relevant categories in a publication exploring differences among
global healthcare initiatives. The first mentioned is the “engineering model,” which “treats
physicians as applied scientists” (Chandra et al, 37, 2010). This approach seems most relevant to
the United States, given the tendency of American healthcare to involve extensive in-patient
treatment versus preventative care. The “collegial model places physicians and patients on an
equal basis,” and is most characteristic of European healthcare systems (Chandra et al, 37, 2010).
Chandra, Willis, and Miller mention other models that apply to less developed nations; however,
these models refer to physicians as “priestly” members of society, and are less characteristic of
Western medicine (37, 2010). Okma and Marmor describe European healthcare as generally
being different than that of other nations in terms of focusing on addressing medical issues
preemptively. Willis, Miller, and Chandra, whose collegial model of patient/physician equality
seems particularly characteristic of Western European nations, support this.
Healthcare in the European Union
With this research in mind, a cross-country comparison of European healthcare systems
provides us with a strong starting point for this research. Looking back through time, public
health in the European Union has generally improved in the post-World War II years up to the
present. Many different variables such as an increase in income, the absence of war, and the
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availability of new technologies are just some of the things that can explain this. Even though
aggregate European healthcare has become some of the best in the world, there still exist many
differences among individual European nations, as well as a lack of a standard European Union
healthcare policy. This has led to pronounced differences in the efficiency of healthcare systems
across the continent.
In 2010 professors Laura Asandului, Monica Roman, and Puiu Fatulescu evaluated the
efficiency of public healthcare in Europe, using Data Envelopment Analysis, a “method which
identifies an efficiency frontier on which only the efficient Decision Making Units are placed, by
using linear programming techniques (sic)” (Asandului et al, 2010). Their study included “life
expectancy at birth, health adjusted life expectancy, and infant mortality” as “output variables,”
as well as “number of doctors, number of hospital beds, and public health expenditures as
percentage of GDP [Gross Domestic Product]” as “input variables” (Asandului et al, 2010).
Their results indicate that healthcare efficiency in Europe seems to be relatively independent of
the respective input variables of this study. One such indication from their conclusion was that
“the number of physicians ranges from 19.2 physicians per 10.000 inhabitants in Romania to
60.4 physicians per 10.000 inhabitants in Greece (sic),” yet the former nation ranked sufficiently
higher in overall efficiency when compared to the latter (Asandului et al, 2010). Another study
conducted in 2011 by professors Sharon Hadad, Yossi Hadad, and Tzahit Simon-Tuval
employed a similar method of research to that of Asandului and her colleagues, but instead
looked at a number of OECD (Organization for Economic Co-Operation and Development)
countries, rather than exclusively looking at nations in Europe. These researchers examined
healthcare efficiency, or lack thereof, as being the result of “inputs considered to be within the
discretionary control of the healthcare system,” as well as the lifestyle habits and behaviors of

12

individuals (Hadad et al, 2011). Using a similar type of Data Envelopment Analysis as to what
was done by Asandului, Hadad and her team created two distinct models for their research, with
the first studying only inputs of the healthcare system. Results from this model show consistent
findings with those of Asandului, although it is noteworthy that German healthcare efficiency
ranked significantly lower than many other OECD countries in this model. Nonetheless this
model indicated that in terms of healthcare inputs, all OECD countries are fairly efficient. Many
nations in Hadad’s study earned an efficiency score higher than 80 percent, with the lowest
scores tending to range from 60 percent to 70 percent.
Hadad’s second model was structured the same way as the first, and ranked healthcare
efficiency in those same OECD countries based only on lifestyle choices. The results of this
second model were more interesting than that of the first, and countries’ efficiency scores in this
model were all over the place. Some of the highest scores were in eastern European nations
(Poland, the Czech Republic, and Slovakia), while western European countries (including Italy,
Denmark, and Iceland) ranked much lower. Hadad’s model gave the Czech Republic, the top
performer in this model, an efficiency score of 95 percent. On the other hand Greece, which
ranked lowest out of all OECD countries studied in this model, earned a score of 46 percent.
With respect to determining European healthcare efficiency, the second model created by Hadad
had the most interesting and relevant results of the two. Although Hadad’s institutional model,
along with the one used by Asandului had results that were intriguing, both of these models
showed that most European countries tended to cluster around the same area of the scale.
Hadad’s lifestyle factors model showed much greater variation among European countries, and
indicates that individual choices are a critical factor for determining healthcare efficiency in
Europe.
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Having looked upon some of the research done in terms of determining the strength of
healthcare systems in Europe, the next step is to look at research done with respect to healthcare
funding in these nations and the healthcare choices available to residents in those countries.
Researcher Wen-Yi Chen published an article in 2013, which studied patterns of healthcare
spending in OECD countries from 1960 up to 2009 (Chen, 2013). Chen’s research revealed that
European countries studied have tended to strongly support their healthcare systems through
public spending, however Chen’s results also indicate that there were some signs of variation
from this strong pattern of public spending around the 1970s. While public healthcare spending
may have dropped in that period, Chen’s conclusions demonstrate that for most of the nations
studied, the percentage of healthcare funding that was public in 2009 shows little deviation from
what those figures where in 1960. While Chen’s work indicates that European governments are
generally willing to invest large sums of money into their healthcare systems, it leaves the
researcher curious as to how decisions regarding that financing are made, while it also begs the
question of any inefficiency in European healthcare being the result of a poor national health or
funding policy.
In 2014 Mio Fredriksson, Paula Blomqvist, and Ulrika Winblad researched how the
Swedish government administers public health funds, as well as how it encourages good health
practices. Sweden was one of the countries considered relatively efficient in Hadad’s study, and
this is a nation where health outcomes have historically been quite good in comparison to other
countries in the region. Fredriksson’s study shows that local governments and city councils have
traditionally made healthcare policy decisions in Sweden, based on the funding and directions
given to them by the central government (2014). Fredriksson’s conclusions then indicated that
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central high-ranking Swedish politicians in the national parliament have begun to take more
control over how public healthcare funds are managed in the country.
Researchers Valerie Moran and Armin Fidler’s 2009 study detailed the differences in
health expenditures among a number of European countries. Moran and Fidler divided European
nations into three categories based on income, and did a case study on health outcomes for each
of these groups. Their results indicate, as can be expected, that high-income European countries
have better access to emerging treatments and more comprehensive healthcare. Moran and Fidler
then say that these high-income European countries “should provide technical assistance” and
otherwise help lower income countries to access better health technologies (Moran and Fidler,
141, 2009). Among the high-income countries that these researchers mention are Sweden, Italy,
and the United Kingdom. Each of these nations has a well-developed healthcare system by
international standards, yet there are significant differences among the three. Professors George
France and Francesco Taroni conducted a case study of Italian healthcare in 2005, which
revealed that “the pace of change in the [Italian] healthcare system has accelerated” (France and
Taroni, 169, 2005). The change that Taroni and France mention is not necessarily good change,
as their case study reveals that there are many regional differences in healthcare within Italy,
meaning that quality of care is somewhat inconsistent throughout the country. France and Taroni
refer to this as a “decentralization process,” and imply that if this continues at the current rate,
Italy could face a major healthcare crisis (France and Taroni, 182, 2005). Looking back to
Hadad’s study, we can see evidence of this in the efficiency rankings created by her and her
team. Italy earned a score of 82 percent in terms of the efficiency of the healthcare structure
(Hadad et al, 2011). Shifting gears slightly, Frediksson’s article on the Swedish healthcare
system implies that Sweden has a significantly better healthcare structure than Italy, which
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results in a greater level of healthcare system efficiency. Thinking once again to Hadad’s study,
one can see that Sweden had one of the most efficient healthcare systems in Europe (Hadad et al,
2011). Looking at the United Kingdom, a system similar to the Swedish one can be seen, yet
with its own share of structural issues that are reminiscent of the Italian system.
According to a 2014 British nursing publication, the United Kingdom’s National Health
Service (NHS) has become fragmented, and is beginning to show regional differences like what
we see in Italy (Reed, 23, 2014). The article refers to “devolution” in British healthcare policy,
which according to Reed, means that the central government is becoming less involved in
healthcare issues around the country (24, 2014). Reed even points out that “policy variations”
have become so great that fundamental aspects of the healthcare system such as prescription drug
coverage are very inconsistent in Northern Ireland, Scotland, Wales, and England (24, 2014).
Nonetheless, the United Kingdom remains one of the better countries in Europe in terms of
healthcare outcomes and policies, even though the NHS seems to have had better days.
Considering these arguments, it seems that a common European Union healthcare policy would
help governments coordinate and harmonize healthcare services across the continent, which
would ultimately help patients. This is especially true in this day and age, where there are few
practical borders left in Europe. Such open borders mean that trans-national travel in today’s
world requires other cross-national initiatives.
Authors like Reed and Fredriksson argue that structural differences occur for separate
reasons. To Fredriksson, Swedish healthcare efficiency is stronger than that of nations like Italy,
because there is a greater coordination between the central government and local governing
institutions. Reed argues that when it comes to healthcare, devolution of decision-making power
from the center to local governments creates differences in healthcare efficiency, and are overall
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detrimental to national health. Consequently, we can also see the arguments of Taroni (with
respect to Italy) aligning with the points that Reed makes.
HIV/AIDS in Europe and the World
A Global Pandemic
Having looked at previous research that has been done on the structure of global
healthcare systems, a comprehensive review of HIV/AIDS studies in Europe and the world is
needed. One particular textbook that deals exclusively with HIV/AIDS explains that for two
important reasons, treatment for this virus is significantly different than that of other chronic
diseases. The first, as doctors Christian Hoffmann and Jürgen Rockstroh point out, is that HIV is
a chronic condition which requires lifelong therapy, which means that medical expenses will be
extremely significant in the long run, regardless of the prognosis or treatment results (2012). The
second reason is that successful treatment of the virus requires the use of at least three antiretroviral medications (Hoffmann and Rockstroh, 2012). If any fewer anti-retroviral agents
where to be used, the virus would develop resistance to these medications, rendering them
ineffective (Hoffmann and Rockstroh, 2012). Many of these drugs are protected by patents,
which make them extremely expensive to consumers.
HIV/AIDS has shown a global decline in recent years, which has become especially true
of the developed world. Nonetheless, AIDS deaths continue to occur all over the world, and there
are large treatment disparities among nations, especially in the European Union. According to a
report by researcher Hazel Barret, HIV/AIDS deaths have fallen by 25 to 49 percent in a number
of sub-Saharan African countries where AIDS is the leading cause of death (50, 2014). That
same report also indicates that in European Countries like Germany AIDS deaths have declined
by close to 45 percent, while nations like France, the United Kingdom, and Italy have seen
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relatively little change in their annual number of AIDS deaths (Barret, 50, 2014). AIDS deaths
around the world have largely stabilized in the past decade, and we are now looking at a
downward trend of these deaths across the world. Despite this, that decline has not been seen the
same way in the European Union, with some nations in this organization having
disproportionally high number of AIDS deaths and HIV infection rates with respect to other
nations in the European community.
HIV/AIDS in the European Union
Studies conducted in the past reveal that one of the other issues at the forefront of
HIV/AIDS treatment is the problem of treatment resistance. This occurs when the virus is able to
replicate, despite the presence of multiple anti-retroviral agents (Hoffman and Rockstroh, 2012).
Although the chances of this occurring are fairly low when medications are taken as prescribed,
Hoffman and Rockstroh reveal that missing even a few anti-retroviral doses can cause the virus
to become immune to a certain type of anti-retroviral (2012). The real issue arises when a
treatment-resistant strain of the virus is passed on to another person, requiring new and more
expensive medications to combat it. Research by a large team of European scientists revealed
that, on average, 10 percent of new HIV/AIDS diagnoses on the continent are treatment resistant
strains (Frentz et al, 7, 2014). Frentz and his team go on to explain that much of this resistance
does not involve Protease Inhibitors, a newer type of medication used to treat the virus, yet he
also points out that such findings “underscore the importance of baseline drug-resistance testing
prior to the beginning of treatment” (Frentz et al, 8, 2014). The implication from this study is that
while researchers seem to have found a type of medication with a relatively low rate of
resistance, patients must be screened for viral mutations, and must also strictly adhere to their
treatments for them to be effective.
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HIV/AIDS treatments, as well as patient’s adherence to medications, differ significantly
across the world. Previous research in this field suggests that one of the main reasons for this is
differing attitudes and perceptions of the disease. Researcher Ingrid Katz and her team conducted
a study in 2013 to determine what effect HIV/AIDS stigma has on treatment adherence. The
results of her study show that cultural factors play a very large role in whether or not patients
adhere to their medicine (Katz et al, 2013). “Social rejection” was listed by Katz and her team as
one of the greatest reasons for this lack of treatment adherence, though they also point out that
side-effects from the medicine, the use of drugs and alcohol, as well as anger at the HIV
diagnosis play a large role in patients not taking their medicine (Katz et al, 8, 2013). In order to
ensure patients live healthy lives despite their HIV infection, as well as to prevent anti-retroviral
resistance, Katz and her team make a list of suggestions on combating HIV/AIDS stigma. They
point out that “interventions to reduce stigma should target multiple levels of influence”
including “intrapersonal, interpersonal” and “structural [referring to society in general]” (Katz et
al, 1, 2013). Such steps seem to be imperative for any healthcare system to address the issues
associated with treating HIV/AIDS.
Theories of European Integration
Origins of the Union
The end of World War II brought substantial reform to Europe, and one of the greatest
results of this has been the co-operation of European nations. Historically, European nations
have valued symbols such as their national currencies as key to their identity, yet many have
exchanged that for a supranational system that has given some nations less power over their
currency. The theories of European integration examine under what conditions integration may
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take place (as well as what eventual integration may look like), and can be broadly applied
across much of European government structure, function, and public policy.
The European Union as we know it today did not appear overnight. The end of World
War II saw a need for European cooperation, as well as an end to nationalistic rivalries on the
continent. From the 1950s onwards, new international legislation has brought European nations
closer than ever, and in this time period one can also see the inclusion of new member-states to
the now 28 nation-bloc. The origins of the European Union are in the European Coal and Steal
Community (ECSC), which was initially a cooperative industrial policy created by a few
European countries after the war. The Treaty of Rome in 1957 then established the European
Economic Community (EEC), which turned the ECSC into something of a customs union with a
common market. Moving further along in the 20th century, the Maastricht Treaty was agreed
upon in 1992, which created the European Monetary Union (EMU). The later treaties of
Amsterdam and Nice created common rights for all Europeans, and focused on stronger political
integration and supranationalism. In 2007 the Treaty of Lisbon amended the voting procedures of
the European Union, which ultimately governs how new legislation comes into affect in this
political bloc today. Ultimately the treaty of Lisbon may have the greatest effect on the
possibility of a common European healthcare policy; however, this is of course true of the Treaty
of Rome as well, which is the ‘original treaty of the European Union’, so to speak.
In a 2001 publication, professors Jessica Adolino and Charles Blake studied the history of
European integration with respect to public policy. They mentioned that the Treaty of
Maastricht, which was passed in 1991, “formally created” the European Union, and established
common European “economics, foreign and security policy,” as well as “justice and domestic
affairs” (Blake and Adolino, 94, 2001). Blake and Adolino go on to describe the European
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system of decision making as “bureaucratic,” with the European Commission being the most
important government institution of the European Union in terms of integration (94, 2001).
Many theories have emerged as to why Europe has come together the way that it has, as well as
what course of action future integration may take. Blake and Adolino mention several of the
treaties, notably Maastricht and Amsterdam, as being extremely important steps towards
European unity. These same authors point out that these treaties are largely at the root of the
creation of a common monetary policy (also referred to as the EMU or Eurozone), which is the
policy area where we have seen some of the greatest European integration. Given the current
governance structure of the European Union, any common policies that would emerge in the
future would likely emerge from a treaty in the way that the Eurozone did. With that said, the
many theories of integration offer a powerful insight as to how, and if, such common policies are
a possibility.
Functionalist Theories
In a 2000 publication, author Ben Rosamond looked at the most well known of the
integration theories, and analyzed the argument behind each of them. Functionalism and
Federalism are two older theories of integration, which Rosamond starts off his publication by
evaluating. Federalism refers to a concrete division of power between a central government and
smaller, regional governing bodies (Rosamond, 2000). The United States is often referred to as
one of the better examples of a federalist system in practice. Functionalism plays into the
federalist theory (as the former of these two recognizes interests that different states share), and
seeks to create a federal policy to address that (Rosamond, 2000). Rosamond describes these
theories as being less relevant to modern European integration, yet they remain important
because one of the most prominent theories of integration is based off of these two.
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Neo-Functionalism is a theory of integration largely supported by Ernst Haas. Rosamond
refers to the goal of Neo-Functionalism as being the idea “that an international society of states
can acquire the procedural characteristics of a domestic political system” (Rosamond, 56, 2000).
Rosamond further explains this crucial part of Functionalism, which is referred to as Spillover.
Rosamond describes this as a process by which “deepening of integration in one economic sector
would create pressures for further economic integration within and beyond that sector, and
greater authoritative capacity at the European level” (Rosamond, 60, 2000). According to the
idea of Spillover, as originally put forth by Ernst Haas, European integration in one area such as
the European Monetary Union should create an incentive for other sectors of European
governments to integrate, and resort to a supranational system of political administration
gradually emerging.
Haas mentions that this theory refers to integration as “referring exclusively to a process
that links a given concrete international system with a dimly discernible future concrete system
(sic)” (Haas, 29, 1968). Unlike Functionalism, Haas’s theory is less in support of a federalist
type of government, yet assumes that European integration would occur relatively swiftly (1968).
In terms of public policy, we have seen some elements of integration follow a path of action
similar to what Haas mentions. Blake and Adolino point out that in terms of fiscal policy,
countries like Germany were relatively quick to align themselves with supranational guidelines
established by the treaty of Maastricht (2001). These authors also show that such swift change
and integration seems to be the exception rather then the rule (Blake and Adolino, 2001). Blake
and Adolino reveal that in terms of healthcare policy, reform and structural changes to individual
healthcare systems were executed independently by European nation states (2001). In their
overview of 1990s German healthcare reform, these same authors mention that German public
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healthcare spending was cut as the deadline for fiscal restrictions imposed by the treaty of
Maastricht approached (Blake and Adolino, 2001). European healthcare systems looked quite
different from each other at this point in time, and the lack of integration in a policy area such as
this one may be attributable to the financial changes nations were required to undergo to comply
with the Maastricht treaty. Although we can point to specific examples where NeoFunctionalism seems to have worked, examples such as this one do not make it seem like the
best overall explanation for European integration.
Cooperation as an Alternative to Supranationalism
Going back to Rosamond’s analysis of European integration, the next theory he mentions
is Inter-governmentalism. Rosamond explains that European states play a “two-level game,”
meaning that whatever terms one country negotiates with another country, must also be ratified
by both nation’s domestic populations (Rosamond, 135, 2000). The theory of Intergovernmentalism therefore seems to advocate for minimal integration, and instead emphasizes
regional cooperation, believing that whatever integration does take place will occur slowly
(Rosamond, 2000). Thinking back to what we know about European healthcare policy, this
theory seems like a decent descriptor of how far integration in this field has come. Substantive
integration is not well supported by this theory, and therefore Inter-governmentalism involves
very little in terms of supranational institutions. Rosamond mentions a split in the Intergovernmental school of thought, and emphasizes the existence of a newer twist on this theory
called “Liberal Inter-governmentalism” (Rosamond, 136, 2000). This newer look on Intergovernmentalism, pioneered by professor Andrew Moravcsik, is one of the more complicated
theories of integration, yet has some of the best descriptors of the factors driving integration.
Moravcsik begins his analysis by addressing the other theories we have discussed as “classical
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theories of integration,” and mentioning that his theory is “narrowly focused yet more broadly
generalizable,” believing that its potential for application is greater than that of the other theories
(Moravcsik, 19, 1998). Moravcsik, using primarily the EMU as an example, believes that
concrete integration is favored by European states when there is potential to become financially
wealthier and stronger from it (Moravcsik, 1998). Going off on the European Monetary Union
example, Moravcsik argues that the reason we see such strong integration in this area of
European politics, is because creating a supranational body was desirable to citizens and
governments since the gains to European nations would be immense, yet integration would take
place at more or less the same pace as in Inter-governmentalism (Moravcsik, 1998). If we were
to apply Moravcsik’s theory of Liberal Inter-governmentalism to European healthcare policy,
supranational integration would likely only be possible if there were clear economic gains to
both national governments and their populations.
Ideational Theories of European Integration
In addition to the conventional theories of European integration, there are ideational ones
that should be addressed as well. In a 2014 article professor Tommaso Pavone analyzed these
theories, and provided a strong overview of them. In short, Pavone critiques the work of
European ideational theorist Craig Parsons. Pavone explains that Parsons seems to believe
Europeans came together as result of “eurofederalists (sic)” desiring a stronger sense of
community and being met with less opposition while doing so (Pavone, 2, 2014; Parsons, 1-34,
2014). Parsons’ theory looks at Liberal Inter-governmentalism and Neo-Functionalism as lacking
substantive reasons for European integration (Pavone, 2, 2014; Parsons, 1-34, 2014). Pavone is
quick to point out that Parsons “incorrectly equates” elements of other integration theories with
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his own visions of them (Pavone, 2, 2014). In comparison to the more well known theories of
European integration, the ideational ones seem to get the least recognition and credibility.
At the end of his work, Rosamond synthesizes each of the integration theories, with the
ideational ones, and reflects on which he believes will have the most relevance moving forward.
He concludes that while each theory makes its own relevant contributions to potential future
European integration, “theoretical endeavors on European integration are likely to develop most
fully as sub-sets of other concerns,” meaning that new areas of integration will likely prompt the
emergence of new theories, or new twists on these existing ideas (Rosamond, 197, 2000).
Another thought that arises after considering European integration theory is the question of what
these ideas will mean for the integration of new policies in the European Union. According to a
2014 study on common European policies, it seems that the implementation of current policies
differs significantly throughout countries in the European Union (Voermans, 2014). Differences
in public policy are in line with certain theories, such as Inter-governmentalism, but create
questions for theories like Neo-Functionalism in terms of how strong European integration can
truly become. As Voermans implies, while the European Union does have “treaty based
compliance tools,” it seems that other methods of enforcement may be required to fulfill the
necessary conditions of a theory like Neo-Functionalism (Voermans, 355, 2014). Looking
forward to future European integration, such ideas will likely form an important part of any new
theories of integration that may emerge.
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Methodology
The substance of this research will primarily consist of qualitative studies. First, an indepth look will be taken at the healthcare systems of various European Union member-states, as
well as of the EU as a whole. In addition to closely studying these healthcare systems, this
research will also consist of a quantitative comparison of the strengths and weaknesses of each of
these health care systems. It will then be possible to draw conclusions concerning where the best
overall healthcare strengths exist in Europe. With that in mind, cross-sectional healthcare
information will play an important role in the later discussion and conclusion sections.
Second, an in-depth look will be taken at the quality and consistency of HIV/AIDS
treatment and prognoses in Europe. The countries on the continent with the most and least
effective treatments results for this virus will be analyzed, as will the case of HIV/AIDS across
the European Union as a whole. As with the earlier case study, social and cultural factors
affecting HIV/AIDS treatment will be studied to see if those findings are applicable to other
healthcare systems in Europe, and that of the European Union. Data for these case studies will
come from a number of reputable, international, and scholarly sources. Primarily, these sources
will come from groups such as the World Health Organization, United Nations, and of course the
European Union itself. Additional sources and information published by individual nations will
also be examined. Furthermore, scholarly sources along with differing statistics and perspectives
on healthcare and HIV/AIDS in Europe will be closely examined. In addition to modern data, a
look at historical figures will be taken as well to determine if any evidence supports major trends
of overall healthcare or HIV/AIDS treatment improvement, or lack thereof, in some countries
versus others.
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The primary strengths of this approach are that it will allow for a close analysis of
healthcare systems in Europe, as well as HIV/AIDS treatments. Focusing extensively on these
cases will allow for a stronger study than a simple cross-country comparison would.
Furthermore, this approach will theoretically allow for underlying reasons of success (or failure)
in European countries to become visible. The downside of such an approach is that it will look at
one specific region of the world, and share little information about any other part of the globe.
This means that results will be less relevant for non-European nations, as well as for countries on
the continent that are not members of the European Union.
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Healthcare in Europe
After examining the intricacies behind the theories of European integration, looking at a
nation that has shown itself to be on the periphery of European integration gives my research an
interesting perspective from which it can move forward. A subsequent look at European states
with stronger leanings towards the policies of the European Union should provide an interesting
contrast, and expand upon the questions left open by the previous chapter. Finally, a study of the
aggregate healthcare policies of the European Union will bring about a final important reference
point with respect to European healthcare and HIV/AIDS, allowing me to examine what seems
to work well for each of these entities and what does not.
Great Britain
The United Kingdom is one of the oldest members of the European Union, yet it is a
country that values its sovereignty in a way that is different from the other major powers of that
body. Great Britain is not a member of the Schengen agreement, nor is it a part of the European
Monetary Union (EMU), and its government has generally been against giving up power to a
supranational authority. One of the key aspects of the British model of government, also known
as the Westminster system, is that any and all actions of parliament can be undone. While the
British parliament can choose to devolve its powers of government, those actions are not
irrevocable. For this reason the United Kingdom has been reluctant to join European movements
that involve pooling their sovereignty at the supranational level. The prime example of this
would be the British refusal to partake in the EMU, and to instead continue using the British
pound. British acceptance of the Euro as its currency would involve the Bank of England, which
is a quasi-governmental organization, giving up its power to make monetary policy to another
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entity, and not having the ability to go back on the decision without causing huge financial
issues.
Britain, much like other European countries as I will soon show, has a universal system
of healthcare. The system is referred to as the NHS (National Health Service), which is a
fundamental aspect of the modern British nation. To take something like the NHS away from the
British would strip the country of an important part of its national identity. The same can be said
about the British pound, as replacing it with the Euro as a national currency would undoubtedly
hurt the British cultural image. One key difference between these two policy areas is that the
European Monetary Union has involved some of the greatest integration among member-states
that the continent has seen to this day, but was not a requirement for membership to the
European Union. Unlike the well-integrated EMU, there is today virtually no policy of the EU
that effectively regulates healthcare across member-states; however, should such a policy come
into existence, it would most likely come in the form of a court decision or treaty that memberstates would not have the option to opt out of. For instance, if the European Court of Justice
(ECJ) took on a case concerning healthcare inequality or discrimination among EU memberstates, the resulting verdict could call for more stringent transnational healthcare rules that would
inch the European Union closer to a common healthcare policy. Likewise, if another major treaty
targeting something such as European citizenship where to come about, a clause in such an
agreement could call for stricter policies and procedures on healthcare throughout the EU.
However, such a treaty would likely have to be ratified by each and every member-state in order
to enter into force, and would certainly be a tough sell if put to a national referendum.
Keeping all of that in mind, an in-depth look at the British healthcare system is needed.
Traditionally healthcare in the United Kingdom has been some of the best in Europe, especially
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with respect to chronic diseases such as HIV/AIDS. The British non-profit HIV/AIDS support
network AVERT describes the disease’s current situation in Britain as a massive healthcare issue
for the country (2012). AVERT explains that while overall infection rates have remained
somewhat steady over the past decade, a new surge of infections is evident, particularly among
young white males. These statistics come to light despite numerous advances in HIV/AIDS
treatments, greater awareness of the virus and how it is transmitted, and a greater number of
treatment choices.
For someone infected with the HIV virus in Britain, assuming that they do not seek
treatment in another country, every part of their treatment experience would ultimately involve
the NHS. This means that everything from the initial diagnosis, any prescribing of treatment
medications, and follow-up visits would all likely be handled through the British state-run
system of universal healthcare. The official National Healthcare Service website mentions that
the NHS “was born out of a long-held ideal that good healthcare should be available to all,
regardless of wealth,” and describes itself as one of the world’s largest employers (National
Health Service, 2015). Further information from the NHS indicates that all of its revenue comes
from taxes, and that since its inception in 1948, funding for the NHS has increased by more than
1200 percent adjusting for inflation (National Health Service, 2015). In an article analyzing the
history of the NHS, the British Journal of Healthcare Management revealed that the “financial
burden” it initially caused was overwhelming, and led to a shortage of qualified medical staff in
the United Kingdom (Jones, 78, 2015). The author mentions that in recent times the NHS has
undergone many changes, including new methods of funding, and devolution of some authority
to local governments in England, Scotland, Wales, and Northern Ireland. Nonetheless, the article
establishes that the British central government remains at the heart of the NHS (Jones, 2015).
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The article concerning the history of the NHS concludes with the statement, “it has often been
said that the NHS is a victim of its own success because it created a belief that everyone could
(and should) be cured of whatever illness befell them. But it can also be said that it is a victim of
its own failure—a failure to deliver on the promises of ‘a free universal health service’ made
before its inception” (Jones, 79, 2015). This author is not the only one with such feelings about
the NHS, as many feel that the NHS is inadequate to effectively perform everything required of
it.
Nonetheless the National Health Service promises to provide full treatment to all in Great
Britain, so for someone with HIV/AIDS, the government will cover treatment costs. In addition
to HIV/AIDS patients requiring frequent intensive care, the virus is extremely costly to treat,
which creates questions regarding the effectiveness of the NHS in tackling the virus in all of
United Kingdom. Cost is one of the primary concerns, and according to information provided by
the NHS on one of their health management websites, “it is estimated that without radical
changes to the way the system works, as demand rises, and costs rise too, the NHS will become
unsustainable, with huge financial pressures and debts. If we make no changes we face a £30
billion funding gap for the NHS nationally by 2020” (National Health Service, 2015). Such a
funding gap would create massive problems for those living with HIV/AIDS in the United
Kingdom due to the high treatment costs associated with the virus. Most HIV/AIDS treatment
regimens, referring to the combination of pills that must be taken to effectively treat the virus,
range in price from twenty-thousand to thirty-thousand dollars a year per patient (Horn, 2012).
The virus also requires constant treatment in order to prolong a reasonably healthy life, and any
interruption of treatment can cause future medications to become ineffective against HIV.
Annual costs for HIV patients, when scheduled appointments and blood testing are accounted
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for, can be in the hundreds of thousands of dollars. This creates a huge problem for the NHS, not
to mention those living with the virus in Britain. Should the National Health Service be unable to
cover treatment expenses, Britain could face an epidemic of HIV treatment failures.
Modern challenges facing the NHS include addressing the needs of an elderly generation
that continues to grow, an increasing number of immigrants, and the need for more advanced
treatments. Despite all of the additional government funding that has been channeled to the NHS,
the system today is described as being on the brink of collapse by many. British Prime Minister
David Cameron can be seen in many instances taking extensive criticism for the current state of
the NHS; however, the British parliament has yet to imply that it is considering any sort of
revolutionary reform to the current state of the system. One elderly patient at the NHS described
how she has supported the system throughout her life and believes in equal access to healthcare,
but has seen first-hand the many shortcomings of the system. NHS patient Jenni Murray
describes a healthcare system where those critically injured are often quickly attended to, but
those arriving for regular visits, such as HIV/AIDS patients receiving scheduled treatments, may
be forced to wait for hours (2015). Murray goes on to describe how the resources and employees
of the NHS have become critically stretched and refers to nurses regularly working shifts in
excess of 14 hours (2015). Nonetheless, Murray ends her article saying “I will continue to
support the principle of the NHS. I certainly won’t be arguing in favour of paying £5 to been
seen in casualty, as some have suggested. Free at the point of need is what we are so proud to
maintain (sic)” (2015). Criticisms of the NHS aside, it has proven to be a system of healthcare
that provides to all. Keeping the cost of expensive treatments like those required for HIV/AIDS
in mind, it seems fair to argue that the National Health Service has both financially and
physically saved many patients from a darker alternative. One British doctor named Max
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Pemberton, who has worked with HIV patients in London for many years, describes living with
the disease in the UK as being preferable to having diabetes (Pemberton, 2014). Dr. Pemberton
mentions that HIV treatment has improved to such a level, that “HIV/Aids wards and specialist
units [in the UK] have closed simply because there is no longer the volume of patients to fill
them (sic)” (2014). Pemberton attributes this to the fact that HIV/AIDS can be effectively treated
by taking a few pills once a day, which makes it a far cry from the death sentence that this
disease was in the 1980s. However, Pemberton makes no mention of finances or the cost of
treatment in his article, which can be attributed to the universal healthcare structure of the NHS.
Had the National Health Service not been around to cover the huge treatment costs associated
with the virus, it is unlikely that Pemberton would have ever written this article. In a scenario
where the NHS is no longer able to cover the costs of anti-HIV medicines, the situation for those
living with HIV in the United Kingdom would likely turn dire. Looking forward (regardless of
positive and negative views of the NHS), the question of how the system can handle an
increasing amount of the medicinal and financial problems it faces remains to be answered.
Figure 1 (pg. 90) shows current population predictions for the United Kingdom.
Figure 2 (pg. 90) shows diagnoses and deaths from HIV/AIDS in the United Kingdom in recent
years.
Germany
German history generally does not positively embrace any system where a single person
or entity has any type of supreme power. This is a notion that is at the core of the German
constitution and flows into all aspects of German government and public policy. In the United
Kingdom we saw a fusion of powers, meaning that all power is vested in a single entity (the
British Parliament), and that any devolution of power from that entity can always be undone. A
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division of powers instead characterizes the German system, with a greater emphasis on balanced
decision making. This notion is seen in the German healthcare system, which displays many
differences from what we saw with the National Health Service in Britain. One 2015 publication
from the London School of Economics and Political Science provides a substantive overview of
the many different healthcare systems in Europe. The authors of this publication describe
healthcare in Germany as consisting of a national health insurance system, in which there are a
number of different providers, but individuals are legally required to participate in one or more
of them (Mossialos et al, 2015). Much like the Affordable Care Act in the United States, the
system is extremely complex and consists of multiple insurance providers including employers
and the government. In addition to being required by law, healthcare coverage is guaranteed to
all in Germany, but is not administered by a single private or government entity. Instead, the
many aspects of healthcare are broken down into options and services provided by regional
governments and some private entities (Mossialos et al, 2015). Separation of responsibility and
authority regarding healthcare reflects one key aspect of powers being separated in Germany.
The immediate consequence is that individuals are guaranteed more freedom and a better choice
of treatment options than what they may face under systems such as the NHS in the United
Kingdom; however, this also means that treatment experiences will show variation across
Germany.
Everyone is required to have health insurance in Germany. However, the conditions and
regulations governing which plan one must choose are complex. According to the international
organization that seeks to provide information to those looking to live abroad, InterNations, one
must obtain public health insurance in Germany, unless one of two conditions are met: your
“gross income has exceeded the yearly limit of 53,500€ for the past three years,” or “you have
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not participated in any EU member-state’s public health insurance plan for at least three years
out of the last five years (sic)” (InterNations, 2015). In the event that either of these conditions
applies to an individual, that person must obtain private health insurance. In short, “signing up
with a public health insurance company is relatively easy, you don’t need a health check
[referred to as a physical in the United States], and preexisting conditions never form an
obstacle” (InterNations, 2015). However, public insurance in Germany will limit the options that
a patient has in terms of which doctor they want to see, or which hospital they want to undergo
treatment at. Private insurance, although more expensive, offers a number of benefits such as
“hospital treatment by one of the chief physicians” (InterNations, 2015). Regardless of what sort
of health insurance plan an HIV-positive individual living in Germany takes, they will have
access to quality treatment. However, a patient with private insurance may get a better level of
care, better medications, and more personalized treatment. This creates a situation where the
healthcare experiences of those who are comparatively wealthy will likely be more pleasant and
efficient, while those with lower incomes will likely be subject to long wait times and less
personalized care. More simply, HIV/AIDS treatment in Germany is somewhat analogous to the
choice of buying a car: both a Toyota and a BMW will get you from point A to point B, but the
BMW will make for a smoother ride. In this example a Toyota is the equivalent of public health
insurance and the BMW is the counterpart to private health insurance, but one must remember
that private health insurance in Germany is often not a matter of choice. Therefore, costs and
treatment experiences differ in this country, but not in a way that guarantees better treatment to
any income group.
Official statistics released by the World Bank indicate that Germany has a slightly higher
rate of HIV/AIDS infection than other Western European nations such as the United Kingdom
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(World Bank, 2012). Curiously, another set of statistics released by the CIA (Central Intelligence
Agency) show that in a given year the United Kingdom sees roughly 600 deaths from
HIV/AIDS, while Germany experiences around 400 (CIA World Factbook, 2015). Although the
numbers may seem marginal, these statistics raise the question as to why a country with a greater
rate of HIV/AIDS infections has a lower annual death rate from the virus. Tejas Chhaya and
Andrew Nguyen are two American medical students, who as part of their studies interned for a
month at a hospital in Germany. They describe the German medical system as being
characteristic of greater patient satisfaction and attention from medical staff than what they were
used to seeing in the United States (Nguyen and Chhaya, 2013). These two students further
mention that healthcare in Germany is
more tightly controlled by government oversight. In Germany, reimbursement was
simpler and much more reliable, allowing physicians and the clinics to accurately and
efficiently account for their income and expenses. A higher proportion of health care
expenditures in Germany were also spent on preventative care, as seen in the higher
proportion of primary care physicians in the workforce (sic) (Nguyen and Chhaya, 2013).
For those patients living with HIV/AIDS, preventative care is a crucial part to getting a good
prognosis, and a better quality of life. The German healthcare system is more characteristic of a
closer relationship between patients and caregivers than what we saw in the British system.
Nonetheless, the German model seems not to allow for the same exact type of universal health
coverage that was seen in Britain, raising the question of how a very low-income person in
Germany can afford basic healthcare services.
The answer is simple: government regulation. According to a report by American
National Public Radio (NPR), healthcare costs in Germany are based very closely on one’s
income (Greenhalgh, 2008). Those who earn more money will have to pay a greater chunk of
their income towards health insurance, while those who earn less will pay less (Greenhalgh,
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2008). The author of this NPR piece also goes on to describe that the German government
regulates health insurance to ensure that prices are fair and affordable, and that the state-run
national insurance provider ensures that all have equal access to healthcare (Greenhalgh, 2008).
Although such a statement is far from conclusive, greater interaction between patients and
caregivers can provide an explanation for a lower HIV/AIDS mortality rate, despite a higher
morbidity rate than other similar nations.
As far as public healthcare funding in Germany goes, despite the greater number of
healthcare workers and access to healthcare than we see in other countries, the German
government spends comparatively less tax revenue on its health system. Figures provided by the
World Bank in 2014 show that in Germany, roughly 75 percent of healthcare expenditures come
from public spending (2014). Those same statistics indicate that this number was about 83
percent in the United Kingdom during that same year (World Bank, 2014). Although these
figures only show a rough eight percent difference between the United Kingdom and Germany,
such a number amounts to billions of dollars. Development indicators from the World Bank also
show that in the year 2014, Germans on average (in terms of American dollars) spent roughly
5,000 per capita on health costs, while that amount was about 3,600 in the United Kingdom
(World Bank, 2014). It would be incorrect to say that healthcare in Germany is superior to that in
the United Kingdom; however, the evidence thus far presented shows that patient experiences as
well as factors such as hospital wait times are comparatively better in Germany, though at an
average per capita cost of about 1,400 dollars more than in the United Kingdom. So what
happens to those people who cannot afford those extra healthcare costs? In both the United
Kingdom and Germany a low-income citizen would receive substantial assistance from the state,
which should allow for at least basic health coverage. For someone living with HIV/AIDS in
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either of these countries, personal health expenses would likely amount to more than 5,000
dollars, considering the expensive treatments required for this disease. Theoretically healthcare
services should be the same across the European Union, yet the differences that we see between
Germany and the United Kingdom are some of the smaller ones within this inter-governmental
body. Nonetheless, in terms of sustainability and access to treatment Germany comes out on top.
Now take a large member-state with a system that is similar to both of the previous two, yet is
currently facing a unique migrant and financial crisis. How does a country with radically
different circumstances and issues presented before it provide health services to its people?
Italy
No doubt about it, Italy is a unique place in Europe. Everything from the food to the
culture is extremely different from what someone would expect to see somewhere like the United
Kingdom. Italian history is arguably some of the richest in Europe; Italy’s importance from the
renaissance, to the rise of Mussolini, to the present refugee crisis facing Europe cannot be
overlooked. Throughout its history, this is a country that has transitioned away from and
eventually returned to democracy multiple times, yet this is also a nation with a fairly unusual
system of modern government. Everything from political scandals to frequent collapses of the
government plague the Italian nation today; yet, the country is still one of the wealthiest and
most influential in the world. As can therefore be expected, this is a nation with a modern
healthcare system, but also one that is faced with unique challenges.
Much like what was seen in the United Kingdom, Italy provides a universal system of
healthcare coverage to its citizens. Further information from the London School of Economics
and Political Science shows that healthcare in Italy is financed by the government and covers all
individuals, including “legal foreign residents” in the country (Mossialos et al, 73, 2015). When
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looking at healthcare in Italy, it is especially important to keep non-citizens in mind, considering
that for a number of factors Italy is home to many migrants (many of whom are undocumented),
who will often have extensive medical needs. Although private healthcare options do exist in
Italy, they are not part of the national healthcare system, which limits their access to many
people in the country (Mossialos et al, 2015). Statistics from the World Bank show that in 2014
public spending accounted for 78 percent of all healthcare expenses in the country (2014). This is
particularly interesting when thinking of other nations like Germany, which in theory do not
have a state-run system of healthcare, yet do have an almost equal amount of public spending
going towards healthcare as what is seen in Italy. In terms of HIV/AIDS, very few statistics are
available regarding the disease in this country; however in 2013, the CIA World Factbook put
Italy as having roughly a .28 percent HIV/AIDS prevalence rate among the adult population
(2013). Despite the lack of further statistics regarding the virus in this nation, information from
healthcare patients in Italy show what those infected with HIV/AIDS must deal with.
One Italian patient named Susanna describes the system as being “far from perfect,” but
also being characteristic of a democracy that provides healthcare to all its people (Steeves, 2015).
Susanna further describes the Italian healthcare system as consisting of very long wait times, as
well as being riddled with scandals, many of which involve hospitals operating under unsanitary
conditions (Steeves, 2015). Another Italian individual mentions that healthcare quality varies
significantly in Italy depending on what part of the country you are in. Italian healthcare in the
Alps region is supposedly much better than the care one can expect to experience south of Rome
(Steeves, 2015). One of the likely explanations for this is that in recent years the Italian
government has devolved a lot of power to regional authorities, which has contributed to large
differences in healthcare quality across the country.
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One study conducted in 2013 did a quantitative analysis of healthcare quality and
differences across Italy, hypothesizing that in regions of the country where health care costs are
generally reimbursed to individuals and hospitals by the government at a fixed rate, quality of
care will be higher (Cavalieri et al, 2013). The researchers in this study describe that healthcare
in Italy has seen a lot of regional devolution in recent years, meaning that many health standards
as well as payment methods are determined by regional governments, and are thus subject to
variation (Cavalieri et al, 2013). After performing a statistical analysis, the researchers in this
study found that their hypothesis was confirmed by the data, and that there is evidence to suggest
that regions of Italy with greater government financial influence on the healthcare system led to a
greater quality of care (Cavalieri et al, 2013). Another study conducted in 2012 showed that the
European financial crisis has sped up devolution of healthcare power to regional entities across
Italy, which has resulted in cost-cutting initiatives across several Italian regions (Giulio de Belvis
et al, 2012). One of the most significant of these is a “reduction in investments for preventive
medicine,” which can have catastrophic effects for many patients (Giulio de Belvis et al, 2012).
In terms of HIV/AIDS treatment, preventative care is a crucial aspect to a good prognosis. If
efforts are not made to preventatively treat the spread of the HIV virus, it will not only continue
to spread among the population, but will also likely develop into AIDS at an accelerated rate.
Further information published by Italian physician Fransesco Traina reveals that “Italy has the
highest number of physicians subject to criminal proceedings related to malpractice” in Europe
(1, 2008). Traina mentions that many of these cases occur in locations where hospitals are
understaffed and underfunded (2008). Needless to say, the implications of medical malpractice
can be detrimental not only to the prognoses of HIV/AIDS patients, but also to the healthcare
system as a whole. Traina’s article was published in 2008, which was just as the financial crisis
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was occurring and healthcare devolution was beginning. Given the current state of income
disparity in this country, it is unlikely that the rate of medical malpractice has declined. Unlike in
the cases of Germany and the United Kingdom, there is little evidence and resources available to
document the statuses of HIV/AIDS treatment and healthcare quality across Italy. Furthermore,
the fact that healthcare devolution is continuing in Italy means that regional governments will
have far more control over the budgets and procedures regarding healthcare occurring in these
regions. Given the income divide in Italy, this is a huge problem.
Figure 5 (pg. 93) shows the distribution of income across Italian states.
As Figure 5 shows, healthcare in the Northern parts of Italy generally face a better
financial situation than their counterparts in the South. Assuming the devolution of healthcare
authority continues, this will mean that inequality will persist and expand in Italy, and could
possibly lead to a healthcare crisis should quality of care cause individuals in the South to seek
treatment in the North. This of course raises the question as to why healthcare in Italy, which is
still technically considered to be a universal system of care, has been subject to such extensive
regional devolution. One potential answer is the impact of political scandals in the nation, and
the national government seeking to ease the difficulties that it faces. The European Monetary
crisis, the migrant issue, as well as weak GDP growth have all put extreme pressure on the
Italian state in recent years. This makes it not altogether surprising that the national government
would choose to devolve healthcare authority, which it has less pressure to address than say the
economic situation, to regional entities. The migrant crisis can also help to explain why
differences in healthcare quality vary so greatly across this country. The geographic location of
Italy creates a situation where the northern part of the country becomes home to significantly less
migrants than the southern part of the nation. Given the distribution of population, and thus need
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for healthcare services, devolution of healthcare authority in Italy is a good solution for relieving
pressure off of the national government; however, there is no denying that such devolution has
caused the Italian model of healthcare to become inconsistent and less characteristic of a truly
universal system, as well as provide unequal levels of healthcare quality across the country.
The European Union
From Nice to Amsterdam, then down to Lisbon and back up to Maastricht; Europe is
arguably closer today than it has ever been in the past. While European history is full of stories
of empires conquering the continent; the Europe of today is held together by a free coalition of
democracies brought together by a desire for peace and prosperity. For better or worse, one must
acknowledge that the European Union has become far more influential and successful than what
the European Coal and Steal Community in the 1950s could have envisioned. As we have
discussed, some realms of policy making have seen an extreme level of integration across this
inter-governmental body, while others have seen relatively none.
In terms of healthcare the official policy of the European Union is to leave it to “national
governments to organize healthcare and ensure that is provided”; however, the European Union
does acknowledge the need to tackle cross-border healthcare issues (The European Union, 2015).
Out of all of the EU legislation that exists, a considerably small amount of it deals with
healthcare across the supranational body. Article 168 of the “Treaty of the Functioning of the
European Union” explains that member-states should cooperate with one another in
implementing cross-border healthcare; however, there are no explicit policies in the legislation
that dictate specific cross-border healthcare procedures that must be undergone (The European
Union, 123, 2010). While the article does set up some basic aspects for cross-border healthcare
initiatives to occur, it gives little information as to a timeframe when such programs should
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begin, nor what sort of involvement the EU government in Brussels will have aside from
encouraging these developments. More simply put, the official statement that the European
Union has made regarding healthcare policy in general is “the EU does not define health policies,
nor the organisation and provision of health services and medical care (sic)” (The European
Union, 2010). Instead, its action serves to complement national policies and to support
cooperation between member countries in the field of public health (The European Union, 2010).
The issue with Article 168 is that it ignores the obstacles that exist in terms of encouraging crossborder healthcare initiatives. One scholarly article demonstrated that in most European countries
public spending on healthcare increased dramatically prior to the 1970s, which was followed by
many nations cutting their public health expenditures (Mossialos et al, 2002). Their study shows
that one of the greatest challenges to a trans-European healthcare policy is harmonizing public
spending across the EU. The authors demonstrate that in recent times, public healthcare funding
has increased by over eight percent in some EU countries, while simultaneously decreasing at a
rate of almost four percent in other member-states (Mossialos et al, 2002). Article 168 leaves
most healthcare decision making power at the national government level, and creates a
framework that gives little guidance or incentive for any member-state to lead a movement
towards a rigidly defined system of supranational care.
Considering the analysis of the UK, Germany, and Italy conducted, it can be said that one
great issue in Europe is the lack of a standard level of healthcare across the EU, which is evident
by the German healthcare system ranking ahead of that of the UK and Italy, respectively.
Looking forward, there are plans to make healthcare in the EU more consistent and accessible
across borders, but these actions come across as being more theoretical than practical. In March
of 2011 the European Parliament issued a directive intending to harmonize healthcare across the
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union, yet this directive did relatively little in terms of changing actual policies. Although the
right of all European citizens to healthcare in other member-states is established by the policy, it
is explicitly noted that “member-states retain responsibility for providing safe, high quality,
efficient and quantitatively adequate healthcare to citizens,” which establishes that healthcare
authority is essentially an exclusive power of national governments (European Parliament, 1,
2011). The directive also goes on to mention previous rulings of the European Court of Justice
(ECJ), and establishes that patients do have a right to be reimbursed for healthcare costs incurred
in another member-state (European Parliament, 2011). Information for citizens regarding these
rulings are provided by the European Commission, which states “patients will be allowed to
receive treatment in another EU country and be reimbursed without prior authorization for
hospital care however, under certain circumstances, a Member-state may decide to introduce a
system in which patients require an administrative prior authorization before seeking care
abroad” (European Commission, 2008). Nonetheless, it is also made explicitly clear that “the
patient will have to pay the costs to the healthcare provider abroad up front, but will have those
costs afterwards reimbursed up to the level of reimbursement for the same or similar treatment in
their national health system” (European Commission, 2008). The problem with such a policy is
that it essentially leaves finances in limbo, and puts patients at the mercy of the healthcare
system in any given member-state.
If patients have to pay up front for healthcare in a member-state other than their own,
what happens when they are financially unable to do so? Furthermore, if a patient from a state
that is a member of the European Monetary Union pays for treatment in a member-state that does
not use the Euro as its currency, what should happen in terms of reimbursement when either
country’s currency fluctuates? Unanswered questions such as these show us some of the
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problems of supranational integration. In terms of current and future possible policies, the
European Union is certainly not perceived the same by all of its citizens. For a number of
reasons, many Europeans have an apathetic or less than favorable view of the European Union.
Figure 3 (pg. 91) shows favorability and perception of the European Union in member-states as
of 2015.
The evidence so far studied suggests substantial differences in healthcare across the EU.
If one takes another look at Figure 3, the question can be asked: would a more effective policy
on healthcare improve favorability of the EU? Just based on Figure 3 and the expenses it would
take to implement any such policy, the short answer would probably be no. However, if a
common policy would ultimately create a better framework across the continent that improved
on inefficient healthcare systems, the answer might be different.
In most countries of the EU, public spending plays a major role in healthcare financing.
Trust and confidence in the government varies significantly across member-states of the EU,
which plays an important role with respect to how a supranational healthcare policy might be
perceived. In 2014 the World Values Survey Association studied what percentage of the given
population in a country have feelings of confidence about their government, and ended up with a
range of different results in EU member-states. An average of 36 percent of citizens surveyed in
European Union countries expressed confidence in their national government, with Slovenia
ranking lowest at only eight percent (World Values Survey, 2014). The World Values Survey
then indicated that Sweden and Finland were the highest-ranking member-states, with both
nations showing 64 percent of survey respondents expressing confidence in their governments
(2014).
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Connecting that back into healthcare, one can also see a great variation in out-of-pocket
healthcare expenditures across the European Union. According to figures published by the World
Bank in 2014, an average of 20 percent of healthcare costs were paid directly by European
citizens (World Bank, 2014). At 49 percent Cyprus had the highest average number of out-ofpocket healthcare costs, while the Netherlands had the lowest at 5 percent (World Bank, 2014).
For someone living in the Netherlands, healthcare expenses in a country like Cyprus would seem
astronomical. Under the current system, a Dutch person receiving healthcare in Cyprus is likely
to be faced with a very steep medical bill that they would have to pay upfront in order to receive
treatment. However, it is important to note that a Dutch person-seeking healthcare in Cyprus
would possibly have a wider range of options, and a potentially greater number of treatments to
choose from compared to what they have back home. Curiously, those statistics published by the
World Values Survey show a 47 percent government approval rating in Cyprus, while that figure
was only 35 percent in Holland (2014). There are many factors beyond healthcare that influence
confidence in government, yet financial well-being is one of the most critical of these. If citizens
in nations such as Slovenia and Holland generally feel less confident about the policies of their
government, it is possible that they would be more open to accepting a supranational European
Union policy in a field like healthcare.
In terms of the treatment of HIV/AIDS, the current state of universal healthcare systems
in countries like the United Kingdom and Italy may soon pose a very serious threat to those
living with the virus. In 2003, the World Health Organization (WHO) determined that
HIV/AIDS cases in Western and Central Europe had “doubled to almost 170,000” cases since
1995 (World Health Organization, 47, 2003). Today those numbers are substantially higher, with
early 2015 estimates from the WHO indicating that these figures in Western and Central Europe
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have risen to roughly 900,000 infected individuals (World Health Organization, 2015). Further
information from the non-profit HIV/AIDS support group AVERT indicates that although the
rate of HIV infection in Western European countries remains high, the number of AIDS deaths
has generally decreased (2014). While this is good news in terms of treatment effectiveness, the
future situation does not look as positive across the European Union. Should universal healthcare
systems, such as the British NHS, reach some sort of a breaking point there is a very high
probability that HIV patients will bear the brunt of such failure. The high treatment costs
associated with the virus (and the intensity of care generally needed coupled with the lower
income status of many infected individuals) could spell disaster should any of these systems
collapse.
Despite all of the speculation, universal systems in nations like Britain and Italy continue
to function and provide the services necessary. Given the current relative political and economic
wellbeing in Britain, the odds of the NHS being unable to provide coverage to those that rely on
it is fairly slim. However, in a place like Italy the same cannot be the said. The Italian state is
already under significant pressure from the present migrant and monetary crises; should these
issues further deteriorate, or if another crisis emerges, the healthcare system could face a massive
funding shortage. With the lack of a common European policy to guarantee effective treatment in
the event that this would occur, such a scenario could have a devastating effect on a nation like
Italy, or the many other EU states that are dealing with similar problems.
The European Union has made efforts to address the need for greater access to treatment
for patients living with chronic conditions, and has outlined some of the issues that the intergovernmental body faces with respect to HIV/AIDS. The European Centre for Disease
Prevention and Control (ECDC) released a special report in 2012, which indicated that roughly
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“more than 85% of those diagnosed with HIV [in European Union member-states] and known to
need ART [referring to HIV treatment] receive it” (ECDC, 4, 2012). The report emphasizes that
while this a great improvement over previous years, many problems with respect to treating the
disease continue to exist. The report mentions that “members of vulnerable and marginalised
populations in EU/EFTA countries find it more difficult to access HIV treatment, care and
support than members of the general population. In EU/EFTA countries, this was reported to be
the case by civil society respondents in almost all countries [88%] and by government
respondents in almost two thirds [64%] (sic)” (ECDC, 4, 2012). The report goes on to mention
that while the lack of access to treatment certain groups face “does not appear to be particularly
due to laws, regulations or policies,” there is still a situation where “antiretroviral therapy is
reported to be available to undocumented migrants in less than half of the EU/EFTA countries”
(ECDC, 4-5, 2012). As is indicated by the publication, the European Union is interested in
improving access to healthcare across member-states; however, this report and others like it do
little to suggest new powerful initiatives.
Considering that laws and regulations seem to have little to do with preventing certain
groups across the European Union from accessing healthcare, an agreement among memberstates is not likely to have an improving effect on the situation. There are of course many other
variables that contribute to why certain people are unable to get the care that they need, such as
treatment stigma, fear of deportation, and an inability to navigate the healthcare system. All of
these factors are extremely relevant with respect to HIV/AIDS, especially considering the
cultural effects that this virus has had on societies. There is no doubt that healthcare quality, cost,
and reliability vary significantly across the European Union; however, national governments and
the European Union need to address more than just the healthcare aspects of policy, especially
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with regard to the treatment of something like the HIV virus, should they hope for the situation
to improve across the continent.
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HIV/AIDS Treatments and their Cultural Influences
Stereotypes and prejudices are found in all aspects of life, and the healthcare field is
certainly no exception to that. Perhaps the most classic example of healthcare stigma is a fear to
touch someone with leprosy, for fear of contracting the disease. However, modern healthcare
stigma is much more apparent and abundant than many think, even for ailments as simple as a
common cold. Imagine having dinner with a friend, who arrives coughing and sneezing. More
likely than not you would refrain from touching them, and would be very careful about not
sharing food with that person. However, in reality your friend may not be contagious, and could
instead be suffering from chronic allergies. It seems like a silly example, but such a situation
illustrates on a very small scale what healthcare stigma is like. Even when we may have no
chance whatsoever of becoming sick ourselves, we tend to avoid and develop misconceptions
about people who are displaying a variety of symptoms. Perhaps more so than any other disease,
HIV/AIDS has been subject to a wide range of stigmas and prejudices.
Understanding HIV/AIDS Stigma & Its Importance
When addressing the issue of prejudices and misconceptions concerning the HIV virus, it
is important to make one important distinction. Both rich and poor countries face similar stigma
issues with respect to this disease, though the conditions and consequences vary depending on
factors unique to the developed and developing worlds. In a wealthy region like Western Europe
as well as in a poor one like Sub-Saharan Africa, a person with HIV/AIDS can face rejection by
society. In the third-world such rejection could motivate an infected individual to commit a
terrible crime such as rape, given the belief among some cultural groups that having sex with a
virgin can cure HIV/AIDS. The developed world is much better informed regarding the disease
and how it is spread; yet, this has only had a small effect on mitigating the stigma of this disease.
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The resulting stigma in a region like Western Europe can scare a person away from seeking
treatment for the disease, which results in the virus spreading further. In terms of stigma the
situation in Western Europe is not nearly as problematic as it is in sub-Saharan Africa; however,
stigma remains a crucial and under-investigated part of the HIV/AIDS problem in Europe, and it
is something that the European Union must address if it seeks to develop a policy to effectively
regulate healthcare and manage this disease.
According to the HIV/AIDS support organization AVERT, the primary reason for stigma
with respect to HIV existing in the developed world comes as a result of “very little” information
being “known about how HIV is transmitted, which made people scared of those infected due to
fear of contagion” when the virus first came to light in the 1980s (AVERT, 2015). Individuals
from this organization go on to explain the importance of recognizing such stigma, as well as the
effect that it continues to have today, even after much more knowledge about HIV/AIDS has
become available. Experts at AVERT mention that stigma can cause a patient to receive poor
health treatment, experience depression, and face discrimination (AVERT, 2015). Although the
stigmas that exist in the European Union are largely different from and may seem less harmful
than those that are prevalent in the developing world, the most basic type of stigma can have a
tremendously negative effect. Some of the most common misconceptions in the European Union
include the belief that HIV can be passed by casual contact, that an HIV/AIDS diagnosis is
synonymous with a death sentence, and that HIV infection only occurs in certain social or ethnic
groups. Unlike with other diseases, false beliefs about how the HIV virus is spread are much
more common among educated individuals than misconceptions about other diseases.
One of the main reasons for this is the fallacy that correlation equals causation.
HIV/AIDS tends to occur in higher numbers among the poor, homosexuals, and drug users.
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However, there are established reasons for this, and it is not true that the HIV virus only occurs
in these populations. Lack of adequate healthcare knowledge and access to condoms has helped
explain why the virus tends to occur more frequently among non-affluent populations. HIV must
enter the bloodstream in order to reproduce. The lining of the rectum is extremely fragile, subject
to bleeding and tearing, and not intended to be subject to intense friction. Hence a tendency to
participate in anal sex provides one of many explanations as to why the disease occurs more
frequently in homosexuals. Lastly, many drug users tend to inject narcotics directly into their
bloodstream. The sharing of needles between individuals in a non-sterile environment therefore
provides an explanation as to why HIV/AIDS is common among illegal drug users. All of these
correlations are constantly mistaken as being the cause of, and sole way to be infected by, the
HIV virus. In actuality, the virus is capable of spreading to any and all individuals; however, it
all ties in to blood on blood contact and probability. The chance of an injection drug user coming
into contact with an infected needle is much greater than the probability of a nurse being
accidently stuck by a misplaced needle while on duty; yet, both of these situations can cause the
virus to spread from person to person. In places like the European Union it is commonplace to
think that healthcare systems are well regulated, and that the right thing is always done in
hospitals. Yet, as the earlier case study of the Italian healthcare system in particular proved, no
country is immune from accidents or health system scandals. Such reasoning helps to explain
why HIV/AIDS stigma is so prevalent in the developed world, despite the fact that information
about how the disease is spread is readily available to the public.
Stigma has become such a large obstacle to the treatment of HIV/AIDS that the United
Nations Programme on HIV/AIDS (UNAIDS) has devoted entire publications to the issue with
respect to tackling the spread of the disease. Throughout the European Union, as well as any
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other country on the globe, UNAIDS makes it clear that “reducing HIV-related stigma and
discrimination is critical in ensuring proportionate and equitable access to services to those most
affected” by the disease (UNAIDS, 5, 2014). Further information from UNAIDS details methods
that can be implemented to challenge such stigma, as well as some of the challenges associated
with them. One method in particular recommended by UNAIDS seems like it would be the most
effective at addressing the stigma issue. According to experts from the United Nations, collecting
evidence on HIV/AIDS stigma at the community level, and taking legal action against those who
indulge in it, may be an effective way to target HIV/AIDS discrimination in Western Europe
(UNAIDS, 8, 2014). The obvious issue with this suggestion is the cost and intensity that the
realization of such a project would require, not to mention the difficulties of implementing
something like that at the supranational level. To understand the best way to deal with such an
issue, taking a closer look at where stigma and discrimination are most prevalent in Europe is
important.
In an August 2015 study, professor Heleen French and several colleagues addressed the
issue of whether HIV/AIDS stigma tends to be worse in either rural or urban populations, as well
as what type of treatment such stigma entails (French et al, 2015). French and her colleagues,
who studied rural and urban African populations, determined that levels of stigma experienced
were primarily the same in both of these settings (French et al, 2015). However, these
researchers also discovered that the bulk of HIV/AIDS stigma is related to issues of disclosure
(French et al, 2015). In many African countries, it was difficult for many people to keep their
HIV status confidential due to societal and legal factors in those countries.
Another article took a simultaneous look at the HIV/AIDS stigma in both the developed
and the developing world, and conducted an analysis of whether or not efforts to combat stigma
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have been effective. The authors took a look at twenty-two different investigations conducted on
HIV/AIDS stigma, and analyzed the results and effectiveness of those investigations (Brown et
al, 2003). In the results of their study, these authors point extensively to the difficulties
associated with directly testing stigma in general (Brown et al, 2003). The authors found that
majority of anti-stigma initiatives “did report some positive results,” but that some “also found
negative and mixed results” (Brown et al, 65, 2003). One of the issues with this study is that it
makes little distinction between HIV/AIDS stigma in the first-world versus the third-world, and
is not able to outline a single approach to combat stigma that has a high degree of success in
either of the two. Furthermore, the authors point out that many of the anti-stigma efforts studied
showed “evidence of superficial changes in attitudes based on improved knowledge, but little
change in deep-seated fears” (Brown et al, 65, 2003). The implication of which, is that
measuring deep seated beliefs on such sensitive issues in any country will prove to be extremely
challenging given the inefficient polling methods available to researchers. Nonetheless, another
important takeaway from this article is the researcher’s findings that in most studies of antistigma efforts examined, “information together with skill building is more effective in raising
knowledge levels and reducing some stigmatizing attitudes among the general population, as
compared with information alone” (Brown et al, 65, 2003). If we now apply this data exclusively
to the European Union, where extensive privacy and non-HIV status disclosure laws already
exist, one would think that HIV/AIDS stigma in the EU might be less problematic than
elsewhere.
When we then look back and consider that healthcare systems such as that of Germany
function significantly better than that of Italy or the United Kingdom, with the former often
experiencing fewer healthcare issues and controversies than the latter two, it is not surprising that
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such HIV stigma and discrimination in the EU continues to exist. The People Living With HIV
Stigma Index (Stigma Index), a United Nations affiliated organization, conducted extensive
studies in both Germany and the United Kingdom with respect to how stigma affects HIV/AIDS
interacting with their respective healthcare systems. In the United Kingdom it was found that
“some participants [of the study] reported that they were reluctant to attend hospital
appointments, either because of risk of being disclosed or obligation to disclose [referring to HIV
status]” (Sharp and Hudson, 48, 2010). The report conducted by the Stigma Index in the United
Kingdom consisted of many qualitative studies, while a subsequent study by the same
organization conducted across Germany examined the stigma situation more quantitatively.
While it can be challenging to compare and contrast a qualitative study with a
quantitative one, the Stigma Index analysis of the United Kingdom looked at several respondents
(out of a random sample of HIV-positive individuals), indicating that they faced some sort of
stigma or discrimination from the healthcare system (Sharp and Hudson, 2010). The quantitative
study conducted in Germany revealed that “only 37% of the interviewees [referring to HIV
positive individuals questioned] are sure that medical documents about their HIV-infection are
handled completely confidentially, 49% are not sure and 13% find it obvious that confidential
handling is not ensured” (Vierneisel, 6, 2013). The general theme when comparing these two
studies is that HIV stigma seems like it would be comparatively milder in Germany than in the
United Kingdom, which a relatively stronger German healthcare system could help to explain.
However, a deeper analysis shows us something different, while these two previously mentioned
studies show us key indicators as to where and how HIV stigma has a detrimental effect across
the European Union.
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HIV Stigma in Germany, Italy, and the United Kingdom
Looking at stigma on a country-by-country basis is an area of HIV/AIDS research that
receives little attention. Therefore, it is difficult to acquire and validate statistics on the subject.
The Stigma Index is at the forefront of measuring where stigma exists, and how much of it is
prevalent; however, few other figures can be found regarding HIV/AIDS stigma. Additional
statistics do exist, and while some come from reputable sources, these figures are generated via
polling methods that are not ideal. For this reason, the primary material in this section originates
from The Stigma Index, with additional sources being included when appropriate.
Before conducting research on HIV/AIDS stigma, it was my plan to divide a case study
on the issue into three parts, giving equal weight to Germany, Italy, and the United Kingdom.
Not long into my research, I discovered that there was an abundance of HIV/AIDS groups in the
United Kingdom, including many that seek to directly support affected individuals by targeting
stigma. This was less of the case in Germany, and for Italy it was extremely difficult to find
HIV/AIDS studies and support networks. Given the evidence available, it therefore seemed most
appropriate to study the information that exists for the Italian case first, and then compare and
contrast that with the other two countries.
Very few studies of HIV/AIDS in Italy have been published, however, there is one in
particular that gives insight into rates of infection across the country. One group of Italian
researchers studied the rate and prevalence of both the HIV virus and AIDS in Italy, and came up
with an interesting finding (Castelnouvo et al, 2003). What is of particular relevance about this
study is that it conducted an analysis of HIV/AIDS immediately following the massive
improvements of treatment for the disease that emerged in the year 1996. This researcher’s study
points out that in the period from 1993 to 1996 the prevalence of AIDS (the final stage of HIV-
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infection) in Italy, per 1000 individuals, was 9.24 for females, and 20.45 for males (Castelnouvo
et al, 2003). In the period from 1996 to 2000 the number of female AIDS cases per 1000
individuals with AIDS decreased by about 16 percent (Castelnouvo et al, 2003). However, in the
case of male Italian AIDS patients, the number of individuals diagnosed with this final-stage of
HIV disease from 1996 to 2000 rose by almost 28 percent (Castelnouvo et al, 2003). These
researchers attribute the rise of male HIV infections in Italy, at a time when most of the
developing world instead saw a decline, as potentially being due to “the fact that women are
routinely offered HIV testing during pregnancy and may thus become aware of their HIV status
during the asymptomatic phase” (Castelnouvo et al, 668, 2003). However, one of the issues with
this argument is that it assumes the greater majority of women undergo pregnancy testing, which
cannot be corroborated without additional research.
That aside, the authors also make little distinction between HIV and AIDS diagnoses in
their results; their conclusions may explain a decline in rates of HIV-infection, but leaves the
reader wondering how the prevalence of AIDS among men can increase so rapidly in such a
short time period. Another study of HIV/AIDS infection rates throughout Western Europe shows
that in comparison to other European nations Italy has a relatively low rate of HIV infection, but
a very high comparative rate of AIDS deaths and diagnoses (Harners and Dawnes, 2004). The
authors believe that one of the reasons for this has been intravenous drug use, which is “very
high (greater than 25%), and might be increasing in some regions or cities in several countries
including Italy” (Harners and Dawnes, 87-8, 2004). These authors also point out that a large
number of migrants from Africa, where HIV/AIDS is very prevalent, might also explain why
Italy is so disproportionally affected in comparison to other European nations (Harners and
Dawenes, 87-8, 2004). However, as we will soon see, there is a lack of adequate support,
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initiatives, and statistics on HIV/AIDS in Italy. Addressing a deadly disease, at a time when
healthcare devolution and government scandals are rampant might be another reason as to why
HIV/AIDS is such a problem in Italy.
One of the few HIV/AIDS nationwide support networks in Italy is La Lega Per La Lotta
Contro L’Aids (Italian League for the Fight Against AIDS), an organization that primarily seeks
to conduct research on the disease in Italy. Information from this group is available almost
exclusively in Italian, thereby potentially excluding migrants and citizens of other EU states.
Most materials from this support network indicate that their focus is on research, while also
addressing HIV prevention. Aside from this group and their few affiliates, there is a lack of
nationwide HIV/AIDS support networks in Italy. This, coupled with the fact that it is difficult to
find HIV statistics in this country, gives little hope for Italy ranking higher than the United
Kingdom or Germany in terms of HIV/AIDS treatment effectiveness. The Stigma Index has no
information whatsoever on what the issue is like in Italy, yet considering the large number of
poorly educated refugees that this nation takes in, it seems fair to presume that HIV stigma in
this country may especially target the non-native Italian community. There is some evidence that
this may be the case. Research published in 2015 by La Lega Per La Lotta Contro L’Aids and the
University of Bologna indicated that roughly 61 percent of those living in Italy with HIV/AIDS
that were surveyed keep their HIV positive status a guarded secret (Cerioli et al, 2015). This
study also revealed “more than half of respondents with HIV reported unfair or different
treatment because of their serological [referring to having a positive HIV test] status” (Cerioli et
al, 2015). One of the issues with this study is that it was presented as an “anonymous on-line
questionnaire” to a group that was “82% male” (Cerioli et al, 2015). Considering the nature and
substance of the Italian healthcare system, the actual situation is likely to be significantly worse
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than what this study suggests. This is in large part due to healthcare devolution occurring
extensively in the nation, which is also affected by a system that is below the standards of that of
many of its neighbors. When turning to Germany and the United Kingdom, one can see that
living with HIV/AIDS in Italy is comparatively worse than in Germany or the UK.
As is the case with HIV/AIDS support groups and awareness in the United Kingdom, an
abundance of studies and statistics with respect to the subject are available for Germany. In
addition to what is provided by the Stigma Index, certain government entities and universities
have extensively studied the disease and its treatment in the UK. One of these studies conducted
regarding HIV/AIDS stigma in the United Kingdom addressed specifically what patients thought
regarding their own HIV-status. The study found that roughly 63 percent of those living with
HIV suffered from low self-esteem, and while that number was almost “exactly the same for men
and women,” it was much higher among homosexual and immigrant populations (Sharp and
Patterson, 2014). Tying this back into the Italian case, where the number of undocumented
migrants in particular is very high, one can only assume that feelings of low self-esteem among
those living with the disease in Italy are far more prevalent. Self-esteem is a key indicator of
mental health, and one of the key factors that play into how HIV/AIDS stigma affects treatment
and the experience of the patient. Less information is available regarding HIV/AIDS stigma in
Germany than what can be found in the UK, though there is an abundance of data and statistics
for this topic in Germany in comparison to Italy. One of the key elements of HIV stigma that has
been thoroughly examined in both the United Kingdom and Germany is stigma in the workplace.
This is a particularly interesting area to explore, given that the workplace is one of the most
relevant places for HIV stigma to play into the healthcare system. The average person spends a
huge portion of their time at the workplace, and must interact extensively with people who may
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not be close friends. Stigma occurring in the workplace is likely to be some of the most
detrimental, because of the need to interact with the same individuals on a daily basis. Such
negative feelings, especially in the absence of mental health or caring relatives, can lead to low
self-esteem, and a reluctance for patients to start or continue seeking treatment. Stigma in the
workplace is even more relevant in Germany versus the UK or Italy, considering that health
insurance in Germany may be provided through the workplace in certain cases.
Throughout its various reports, the Stigma Indexed analyzed HIV/AIDS discrimination in
the workplace in both the United Kingdom and Germany. Many HIV positive individuals were
interviewed in the United Kingdom, and though no overarching statistics were provided for this
country, the general result was that HIV discrimination was not as huge of an issue in the
workplace as in other countries (Sharp and Hudson, 2014). One of the main reasons for this, as
described by one individual, is that "the law changed [so] they can’t ask about your medical
history prior to the interview [referring to employment]” (Sharp and Hudson, 2014). Antidiscrimination laws are comparatively strict in the United Kingdom, and the presence of these
laws provides some explanation as to why HIV discrimination is not a major problem in the
workplace. In Germany it was reported that 26 percent of individuals surveyed, because of their
HIV status, experienced discrimination in the workplace (Vierneisel, 2015). It was also made
clear by the report on Germany that “from those who lost their jobs in the year before the
interview [referring to employment] and base this on their HIV-infection, more cite HIV-related
discrimination as the basis for their dismissal rather than HIV-related poor health status”
(Vierneisel, 6, 2015). The Stigma Index continues to have no information regarding HIV
discrimination in Italy, but from the lack of support groups and lack of nationwide attention
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given to the issue, the situation in Italy ranks as being worse than in the United Kingdom or
Germany.
When comparing the functional and procedural characteristics of the national healthcare
systems, Germany came out as the firm leader ahead of the United Kingdom and Italy. However,
the evidence also shows that Germany is lacking in terms of efforts to eradicate HIV/AIDS
discrimination. The German system performs outstandingly in terms of actually treating and
managing HIV; however, cultural and societal factors in Germany continue to be an obstacle to
the successful treatment of HIV/AIDS. On the other hand, we see that Great Britain does
comparatively better in terms of targeting and combating discrimination, yet the National Health
Service is inferior to the German health care system in terms of actual treatment. Italy then ranks
at the bottom, having neither a strong healthcare system, nor positive societal factors that help
those living with HIV/AIDS.
Applying What Works Across the European Union
In terms of creating a common EU policy, exporting what has successfully worked in one
country to other nations is one possible way that healthcare across the European Union can be
improved. However, there are barriers and obstacles to exporting any such policy. In an ideal
situation, the German healthcare system would exist alongside the laws and cultural dynamics of
the United Kingdom, which should work together to create an optimal environment for those
affected by HIV/AIDS and other diseases.
One of the chief issues with exporting either the British approach to HIV discrimination,
or the German method of actually providing treatment, is the cultural barrier. In a country like
the United Kingdom, the healthcare system that is currently in place is a key part of national
identity. When looking at the British example it is true that the National Health Service is
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lacking in key areas, but replacing that system with something different would likely conjure up
a great amount of British dissent, and could be perceived as an attack on the British identity. This
is true as well in other European nations, and is compounded by the fact that the EU is not
extremely popular to many European citizens. According to the Pew Research Center, roughly
52 percent of Europeans view the European Union favorably (2014). It is also made clear by Pew
Research that positive perceptions of the EU have generally improved over the past couple of
years (2014). However, one of the main reasons for this appears to be the effect that the
European Union has had on the economy. According to additional data from the Pew Research
Center, only 26 percent of survey respondents disagreed with the statement that “[European]
integration has favored the economy” (1, 2014). Economic benefits have been one of the
strongest drivers of European integration, which creates an issue for developing a joint
healthcare model. Implementing a supranational healthcare system in the European Union would
be very costly and would likely complicate ongoing treatments across the continent. Looking
back to the European Monetary Union, which is perhaps the best integrated of all current and
historic EU initiatives, the economic benefits were very clear. Considering that this is not the
case for healthcare, strong opposition against any such common policy would be guaranteed to
occur.
Another large issue of hypothetically exporting the German healthcare model to the rest
of the EU is actual implementation. When one takes a look back at the Italian healthcare system,
universal care riddled with problems can be seen. Considering the vast array of scandals and
complications that plague the Italian healthcare system, it is a quite a stretch to believe that
implementing a totally new healthcare system there would be effective. In the case of Italy,
transitioning to different HIV/AIDS treatment system than what is currently in place is likely to
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create a number of treatment interruptions, as well as complicate the method by which Italians
are used to receiving both basic services as well as things as complex as HIV treatment.
When taking a look at the United Kingdom, one can see a system that is marginally better
than what exists in Italy. It is true that the National Health Service (NHS) is in need of some sort
of overhaul, and that changing it to something on par with the German system would be optimal.
However, in the case of Great Britain cultural obstacles to integration become a key issue. As has
been noted, the British view their healthcare system as a part of their identity. Furthermore, the
British mindset towards the European Union is some of the most negative in the EU. Much of
this has to do with the British cultural identity and the reluctance of Britain to adapt certain
aspects of supranationalism. However, the situation is unique in Britain in the sense that Prime
Minister David Cameron has announced that he will hold a referendum in the near future
concerning British membership in the European Union. One source revealed that “support for a
British exit [from the EU] rose to 39 percent, the highest level since 2012, up from 27 percent in
June. That more than halves the ‘in’ lead to 13 percentage points from 34 points in June”
(Faulconbridge, 2015). Support among the British public for exiting the European Union is
unlikely to create a situation where a common healthcare policy is looked upon favorably in
Britain.
Figure 4 (pg. 92) shows popular opposition to the EU in Britain.
The next question to then examine is whether or not cultural aspects can be exported
across the European Union. The evidence thus far examined shows that applying the German
healthcare model across Europe will be nothing short of a difficult, up-hill battle. With that being
said, one can also see that the cultural factors surrounding HIV/AIDS are significantly better in
the United Kingdom than they are in Italy or Germany. Creating a common EU healthcare policy
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may not be an optimal first step in improving the lives of people with HIV/AIDS, nor those
suffering from other chronic conditions across the European Union. However, trying to change
the cultural mindset across Europe may be one of the better steps to take in the short-term, versus
introducing sweeping changes.
Approval of the European Union and its policies by citizens of member-states is
correlated with whether or not member-states feel well off, particularly in terms of the economy.
Approval for the EU made a very publicized fall following the 2008 financial and Greek debt
crises, though it is generally reported that most European citizens do not wish for their country to
exit the EU. This closely ties in to the issue of creating a common EU healthcare policy, given
that such a policy would likely have a high cost and lack initial efficiency, and would likely
create sentiment against the European Union. One Gallup poll conducted in early 2015
demonstrated that roughly 29 percent of European citizens felt that the EU has made their
country better off (Sonnenschein and Kluch, 2015). On the other hand, roughly 33 percent of
citizens felt that their country was worse off as a result of EU membership, while the remaining
37 percent either had no opinion on the issue, or felt that the EU had not made things better or
worse for their country (Sonnenschein and Kluch, 2015). One of the interesting things about this
particular poll is that it was conducted in March of 2015, before the Syrian refugee crisis reached
the level of publicity that it did later that year. The current refugee crisis has left the European
Union tackling yet another major issue, on top of the ongoing debt crisis, which has pitted certain
member-states against each other. The result has been a fall in the approval rating of the
European Union. Another poll conducted in November of 2015 by the organization Survation
showed that “53 percent” of Britons wanted to leave the European Union (RT, 2015). This is a
sharp fall from the 60 percent of survey respondents who indicated in a 2014 Gallup poll that
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Britain should not leave the EU (Sonnenschein and Kluch, 2015). It is important to examine the
United Kingdom in particular with respect to approval of the European Union and the possibility
of exporting a cultural mindset for two reasons. The first is that evidence has shown that British
laws and accommodations have made living with chronic diseases like HIV/AIDS, in terms of
social conditions, comparatively better in Britain than in Germany or Italy. The second reason
surrounds the fact that Britain is one of the most notable member-states to opt out of EU
movements when possible, and has a comparatively high rate of citizens who do not value
British membership in the European Union.
Given the migrant and debt crises that the EU is now simultaneously combating, coupled
with falling support for the European Union by citizens, it seems unlikely that a common
healthcare policy is anything we will see in the near future. For cultural and financial reasons, it
would be very difficult to export elements of the German healthcare model to the rest of the
union, even if this is a model that better helps citizens affected with diseases like HIV/AIDS.
However, a cultural healthcare policy that creates stronger anti-discrimination laws and access to
treatment laws for those suffering with diseases like HIV/AIDS, like what we see in the United
Kingdom, would be easier to implement, and more likely to succeed. Convergence of effective
policies, such as the German healthcare system with the British legal framework governing the
health-care industry, might create the ideal environment for HIV/AIDS treatments across the EU
to improve. With that being said, it is unlikely that any such change can successfully be
accomplished at a time when the EU is facing two major crises and waning support.
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Conclusions
Overview of Initial Findings
This study has focused on the quality and level of HIV/AIDS care and treatment
throughout the European Union; however, the strongest findings were in the conclusions that I
could draw for each case studied. For the United Kingdom, Germany, and Italy I analyzed
healthcare systems and HIV/AIDS treatment. When looking towards the entire European Union,
and considering what sort of supranational healthcare policy might be beneficial, I identified
numerous obstacles that stand in the way of such a policy becoming effective. Furthermore, I
highlighted a number of the procedural and cultural differences among EU member-states, which
affect healthcare, and other areas of European integration.
Summary of Findings in the United Kingdom
In Great Britain I saw a strong healthcare system, which is driven by a notion that
everyone should have equal and fair access to healthcare. Nonetheless, the British National
Health Service (NHS) faces severe funding problems, which as my research showed, will create
an inevitable issue for patients living with HIV/AIDS and other chronic illnesses. At the
moment, treatment of HIV/AIDS is not problematic, in fact some sources I cited in this study
show that it is in a better state now than it has ever been. However, one must also recognize that
the British healthcare system is facing a decline. The NHS will at some point either need to be
completely overhauled, or receive huge increases in funding, because the current system is
becoming unsustainable given the current population and healthcare issues facing the United
Kingdom.
In terms of living with HIV/AIDS, taking financial and procedural healthcare information
aside, living with the disease in the United Kingdom is comparatively better than in Germany or
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Italy. The primary reason for this is the strong legal framework that has been established in
Britain, which provides extensive protection for individuals against discrimination and a denial
of treatment services. Unlike in the other two countries, extensive and effective initiatives exist
in Britain to free workplaces from discrimination, and promote social programs to improve the
quality of life for infected individuals. Perhaps as a direct consequence of that legislation, and
the gradual change in social attitudes that it has produced overtime, the United Kingdom is home
to an extensive number of support networks that provides support to those living with
HIV/AIDS. This means that both the legal and social frameworks in this nation are optimal,
especially in comparison to the Italian and German cases, and are ideal for helping those with the
disease in Britain carry on with their lives.
When looking towards the European Union, and the idea of a supranational healthcare
policy, British opposition to such a prospect cannot be ignored. Public opinion in the United
Kingdom tends to lean against stronger cooperation with the EU. Despite favorability for the
European Union gradually increasing in the United Kingdom over the past few years, the current
European migrant crisis has largely caused that trend to reverse itself. With British sovereignty
from mainland Europe being a key part of what it means to be British, as well as the persistence
of financial and migrant issues in Europe, my conclusions do not support a scenario where the
United Kingdom will adopt any major type of supranational policy, particularly not in a field
such as healthcare, which is not at the forefront of many British citizen’s minds.
Summary of Findings in Germany
Germany came out at the very top in terms of procedural healthcare characteristics.
Quality of care in this country is very high, and the German healthcare system is comparatively
more efficient than that of Italy or the United Kingdom. Curiously, unlike the other two cases,
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Germany technically does not have a universal system of healthcare. Nonetheless, public,
private, and government-backed health insurance schemes allow everyone to gain access to
treatment in this country. Healthcare costs were slightly higher in Germany compared to the
other cases; however, treatment outlooks for HIV/AIDS patients moving forward in this nation
are financially and procedurally more optimistic than in Italy or the United Kingdom. When
looking at the practical characteristics of the German healthcare system, the lives and treatments
of HIV/AIDS patients showed little difference than those suffering from other chronic illnesses.
When it comes to laws and the societal factors that govern life with HIV/AIDS in
Germany, results showed that this country ranked below the United Kingdom, but ahead of Italy.
There are anti-discrimination laws in force in Germany; however, they do not offer the same
effectiveness and degree of protection that those laws offer in the UK. It was also noted that
HIV/AIDS discrimination in the workplace remains a problem in Germany, and that the country
has one of the higher rates of HIV infections in the European Union. This was particularly
relevant for the German case, since some HIV/AIDS patients have access to treatment through
insurance programs sponsored by their employer. Results here also suggested that stronger
German legal and social measures to combat the HIV/AIDS stigma, as well as to promote
treatment of the disease, would help to further bring German HIV/AIDS further to the forefront
of “what works” in the European Union.
Germany is one of the least-hesitant nations in the EU to welcome supranational change.
This contrasts from what was seen with the UK, for instance with the British feeling strong
connections to their currency and healthcare system and being less receptive to change. Germany
is often at the forefront of movements in the European Union, and has usually been one of the
largest drivers of change across the continent. Nonetheless, the European migrant crisis has
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changed the attitudes of many voters in Germany, with anti-European political parties such as the
Alternative Für Deutschland (Alternative for Germany) gaining popularity. Should a common
healthcare policy emerge in the European Union, it is unclear if Germany will lead the way;
however, as was the case in Britain, nationalistic and anti-European movements are an issue
standing in the way of this nation partaking in new cross-border healthcare initiatives.
Summary of Findings in Italy
Italy ranked at the bottom of this study in procedural healthcare characteristics, and in
terms of efforts to combat HIV/AIDS and help those living with the disease. Although Italy does
have a universal system of healthcare, I have shown that the quality of care varies greatly within
the country. Treatment experiences for HIV/AIDS patients are likely to be of much better quality
in the northern, wealthier parts of the country, versus the more economically challenged south.
Devolution of medical authority to regional governments has exacerbated this divide in treatment
quality, and the presence of healthcare scandals in the country continue to drive a wedge in
effective treatments offered to patients.
While anti-discrimination laws exist in Italy, their effectiveness can be described in many
instances as uneven. Both Germany and the United Kingdom had comparatively more effective
laws and measures to prevent discrimination against HIV/AIDS patients than what was seen in
Italy. Another alarming result that this study revealed in the Italian case is that in addition to very
few national statistics about HIV/AIDS prevalence being available, there also exists a glaring
lack of support groups and organizations looking to help those with HIV/AIDS.
Having ranked below Germany and the United Kingdom in each of the investigations
conducted in my study, HIV/AIDS patients in Italy would hypothetically stand to gain more
from an effective supranational healthcare policy than their German or British counterparts
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would. However, the Italian government’s decision to extensively devolve healthcare authority
does not paint an optimistic picture for Italy adopting an EU supranational healthcare system or
more effective framework for stronger healthcare initiatives. The effects of the European migrant
and monetary crises are much more pronounced in Italy than they are in Germany or the United
Kingdom, which creates additional difficulties to any sort of healthcare reform in this nation
emerging in the near future. Furthermore, waning support for the European Union as well as
apathy towards healthcare reform in the face of the two ongoing European crises in Italy will
also create additional obstacles to such reform.
Anti-Discrimination Measures in the European Union
Based on the results of this study, procedural healthcare reform in the European Union
does not seem like the most beneficial outcome for HIV/AIDS patients given the difficulties
involved with implementing such change at the national level, along with the likelihood that
national support for such an initiative would be very weak. Nonetheless, results from the case
studies of the United Kingdom in particular point to another solution, which may in turn help to
generate better care for HIV/AIDS patients in the EU without actual healthcare reform. As
mentioned, anti-discrimination law in the United Kingdom is some of the most effective in the
EU, and has led to HIV/AIDS patients in Britain enjoying comparatively better daily lives than
their counterparts in other European nations. The European Union has also implemented
supranational anti-discrimination laws, though they lack optimal effectiveness, but would be
much easier to amend and reform than cross-national healthcare policy.
EU anti-discrimination law, stemming largely in power from the Treaty of Amsterdam,
“enhances the importance of human rights within the EU legal order, even providing for the
possible suspension of a state where there is ‘a serious and persistent breach’ of human rights”
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(The European Union, 1997). In the Treaty of Amsterdam, the European Union also
acknowledges ongoing racism, particularly towards “resident migrants,” and states that it is the
duty of the European Union to work against this (1997). Nonetheless, the text in this law is
vague, and the EU has never gone as far as suspending a member-state. The Council of the
European Union approved a directive in the year 2000, which supplemented the antidiscrimination terms mentioned in the Treaty of Amsterdam. This directive (also known as
2000/78/EC) is vague in its text, but mentions specific instances where EU power under the
Treaty of Amsterdam can come into effect. 2000/78/EC mentions the need to improve “the
principle of equal treatment between persons irrespective of racial or ethnic origin,” and reenforces that this directive “already provides protection against such discrimination in the field
of employment and occupation” (The European Union, 2000). Nonetheless, in 2008 a proposed
directive on discrimination was developed that would enhance this multi-national organization’s
ability to impose fines on states that do not work against discrimination (The European Union,
2008). Aside from the ability to impose fines on member-states, this proposed 2008 directive is
more specific in its definition of what is illegal, and defines discrimination “based on religion or
belief, disability, age or sexual orientation” as being “prohibited by both the public and private
sector” (The European Union, 2008). The proposed directive goes on to include “social security
and health care; social advantages; education; access to and supply of goods and services which
are available to the public, including housing” as areas in which discrimination are strictly
prohibited (The European Union, 2008). However, the Treaty of Amsterdam only set up a very
basic framework that consolidated provisions laid out in earlier treaties of the European Union.
Therefore, it is from Amsterdam that some of the most relevant laws and procedures of
the EU concerning discrimination can be seen. The Treaty of Amsterdam lays out only basic
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provisions that define discrimination as illegal, and weakly emphasizes how the practice should
be combatted. Council directive 2000/78/EC on the other hand, builds up some of the provisions
that define discrimination and talks extensively about the need for “social protection” and taking
care of “the needs of disabled people at the workplace” (The European Union, 2000). It is
important to note that HIV/AIDS patients qualify as people who are considered to have a
disability. Nonetheless, beyond loosely clarifying that disabled persons are protected from
discrimination by EU law, 2000/78/EC does not define practical measures by which such actions
can be prevented. The 2008 proposed directive would create provisions that should help the EU
take a much more active role in addressing discrimination by increasing member-state initiatives
against the practice. This proposed directive is extensive, and references provisions set up by the
United Nations in terms of recognizing and targeting discrimination (The European Union,
2008). However, given that this directive is only a proposal, it does not have the force of law.
Nonetheless, I have seen that HIV/AIDS discrimination continues to occur at different
rates among member-states in the EU despite these measures. Even though the European Union
theoretically has some power to punish nation-states that do not take more active roles against
discrimination, it has instead implemented other alternatives to combat discrimination. The
European Commission has worked to introduce “anti-discrimination training activities” in
addition to “supporting intermediary actors such as NGO’s [Non-Governmental Organizations]”
(The European Union, 2008). Results of my study imply that in a country like Italy, such
measures would likely be ineffective in combatting HIV/AIDS stigma given the lack of NGO’s
helping patients suffering with this disease, as well as the vagueness and difficulties involved
with implementing blanket anti-discrimination programs. Nonetheless, this policy of the
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European Union remains one that would be much simpler to amend, and make stronger on a
supranational basis than something as grand as procedural healthcare policy.
Keeping the complexities of EU law in mind, it is important to include a quick note on
where legal authority for anti-discrimination policy in the European truly stems. The European
Union has what are considered “primary laws,” which are the various EU treaties that have been
ratified (The European Union, 2016). These primary laws are then supported by what the EU
refers to as “secondary laws,” which are directives and other measures designed to give the intergovernmental body more power to complete the duties granted to it under primary law (The
European Union, 2016). When talking about anti-discrimination measures in the European
Union, the Treaty of Amsterdam is the primary law that concerns this issue. However, the Treaty
of Amsterdam is essentially a revision of many earlier treaties (which can also be considered
primary law), meaning that much of what the Treaty of Amsterdam states comes from earlier
legislation. The 2008 proposed directive, on the other hand, is an example of a proposed
secondary law, which would lend support to what the European Union can do under primary law.
The 2008 Proposed Directive on Anti-Discrimination
The European Commission’s 2008 proposed directive on anti-discrimination policy, also
known as CNS 2008/0140, would enable the EU to take a stricter stance towards discrimination
(The European Union, 2008). Considering that this directive is only a proposal, it does not have
the power of EU secondary law. However, the content of this proposed directive reflects a
realization of the EU that discrimination continues to be a problem within Europe, and that more
needs to be done to address this issue. Although there continues to be a lack of direct
enforcement of anti-discrimination policies at the supranational level by the European
Commission, this entity is able to sue member-states in the ECJ for policy violations. Should this
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directive eventually become a piece of EU secondary law, it is possible that we will see more
cases concerning discrimination come before the ECJ. Nonetheless, one particular case stands
out and sets something of a legal precedent for anti-discrimination law in the European Union.
In 2008 a case concerning discrimination regarding time off from employment was
brought before the European Court of Justice. The initial case, referred to as the Coleman Case,
was based in the United Kingdom, and later brought to the attention of the ECJ (Equality and
Human Rights Commission, 2015). In short, the plaintiff (named Sharon Coleman) had a son
“with a rare condition affecting his breathing,” which required her to take extensive time to care
for her son (Equality and Human Rights Commission, 2015). She was denied time off from
work, despite her coworkers being given time-off when they had requested it, and brought the
case to the ECJ (Equality and Human Rights Commission, 2015). Based on directive
2000/78/EC, such discrimination should have been prevented by the United Kingdom.
According to the Equality and Human Rights Commission, the court ruled in Coleman’s favor,
and issued a ruling stating that the United Kingdom had to amend its anti-discrimination laws to
adhere to those of the 2000 European directive, and Treaty of Amsterdam (2015). The year that
this case reached the ECJ is the same as when that new 2008 directive was brought up by the
Council of the European Union. Should the EU eventually adopt CNS 2008/0140, it would
undoubtedly work with the Coleman case to provide a stronger point of EU secondary law.
The impact of this case cannot be overlooked. The implication is that when national laws
contradict (or are not up to par with) laws of the EU, then the European Commission via the ECJ
can take action to assert the supremacy of its law. As the Equality and Human Rights
Commission explains regarding the Coleman case, “ms (sic) Coleman's victory before the
European Court of Justice has ensured that the UK's disability discrimination law provides

74

protection on the grounds of someone's association (including caring responsibilities) with a
disabled person” (2015). Despite the value of this ruling, anti-discrimination legislation in the
European Union remains weak. Technically speaking, the European Commission did nothing to
enforce the 2000 directive in the Coleman case. The only reason that the decision against the
United Kingdom was brought in front of the ECJ was because Sharon Coleman, not the
European Commission, took the law of the UK to trial.
Looking forward, enforcement practices concerning anti-discrimination laws by the
European Union may benefit tremendously from being stepped up in two ways. The first is for
the European Commission to take a more active rule in ensuring that its directive is being
followed. There are few other cases in the European Court of Justice that touch on discrimination
issues, and it is often individual citizens who are plaintiffs in ECJ cases. If the European
Commission takes a more active role, even via the ECJ, in enforcing its laws, then antidiscrimination practices (particularly in countries like Italy) may improve. Additionally,
enforcement practices may be stepped up by giving the European Commission power to directly
punish member-states for violations, rather than going through the ECJ. Such a provision would
cut down on the bureaucratic aspects that the EU must deal with when enforcing regulations, and
would give member-states a greater incentive to adhere to the existing anti-discrimination laws
of the European Union.
The Problem with Supranational Healthcare Policy
Looking back to the theories of European integration that were discussed in the literature
review, the idea of inter-governmentalism seems to fit my findings the best. The theory of intergovernmentalism says that European states will work together on tackling certain issues, but that
sovereignty will be maintained by the nation-state. Given what was observed in the three cases I
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studied, particularly in Italy, this seems like the most fitting out of the integration ideas studied.
However, that is not to say that the theories of integration discussed earlier in my study are the
only methods by which European integration in the healthcare field may form.
In response to the many “newer” factors that are influencing European integration, or
lack thereof, a new idea of Constraining Dissensus has developed. Authors Liesbet Hooghe and
Gary Marks argue that European integration, as well as its future, revolves around the key idea of
identity (2008). In addition, these authors go on to explain that “most mainstream parties are
more Euro-supportive than voters” and that these parties have attempted to “depoliticize” issues
of integration (Hooghe and Marks, 21, 2008). Keeping once again in mind the notion of a “twolevel game” that is characteristic of European politics, this argument of Constraining Dissensus
provides one of the better summaries for why integration in the healthcare field is not in
Europe’s best interest, as well as how it may harm rather than help HIV/AIDS patients. If we
look at the Italian case in particular, results from my study have painted a picture of a system that
is barely able to get by. In addition to all of the funding issues discussed earlier, the level of
inequality that is characteristic of healthcare in this nation is probably the most important factor
that distinguishes it from its more effective German and British counterparts. Imagine now if
procedural healthcare reform were to take place in Europe. If we look back to the argument of
Constraining Dissensus, it is quite likely that we would see the mainstream political parties
advocating for such a policy, particularly in a nation like Germany. However, the failure of these
parties to de-politicize the issue, as authors Hooghe and Marks mentioned, will become a large
obstacle in the successful implementation of such a policy.
To best explain this, let us imagine a hypothetical scenario where European leaders have
come together in agreement that the German healthcare system in the best in the European
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Union, and that the practices and methods of this system should be implemented across the intergovernmental body. In a nation like Italy (keeping the inequality that this system is characteristic
of in mind) such reform would likely be disastrous from day one. Setting aside all of the blatant
issues of implementation such as funding, integration with existing healthcare practices, and
changes in treatment procedures, popular opposition to such reform would be extremely
pronounced. Considering again my findings in the Italian case, it is quite unlikely that any such
reform would go over smoothly in Italy. The ultimate result would likely be a straining of the
national budget, continued inequality in healthcare treatment across the country, and a need for
other European countries, such as Germany, to provide financial support. Before even bringing
up the issue of Constraining Dissensus, one can quickly understand that such a scenario will not
help any HIV/AIDS patients.
Once such a situation unravels, public support against a universal European healthcare
initiative will be almost guaranteed to decline. Mainstream parties would continue making their
efforts, as Hooghe and Marks mention, to de-politicize the issue (2008). However, in the face of
such high costs and poor effectiveness in implementation, as we would likely see in the Italian
case and as the argument of Constraining Dissensus mentions, such efforts would be futile. The
ultimate result would instead likely be an even larger decline in support for the European Union,
more power going to the far right, and most importantly poorer treatment for HIV/AIDS patients
than what is presently seen.
However, that same view of Constraining Dissensus does shed light on a different aspect
of this question. As author Philippe Schmitter mentions, “no serious threat to the integrity of EU
institutions has emerged and decision-making has proceeded more-or-less unimpeded” (215,
2009). This portion of the argument refers to institutions already in place, such as the European
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Monetary Union, which gives some hope to the prospect of supranational healthcare policy.
Once in effect, such a policy may begin to become effective in the long run. However, the fact of
the matter is that there are too many compounding factors and obstacles in the short-run for such
a policy of healthcare integration to be successful. Furthermore, my study analyzed HIV/AIDS
and healthcare characteristics in only three European countries. In reality, there are many more
nations with unique aspects defining their healthcare policies, such as Greece, Spain, and
Portugal, which may result in even larger obstacles emerging for a policy of healthcare
integration.
Discussion of Results
Is a European Union Cross-Border Healthcare Policy Practical?
The ultimate results of my study suggest that a supranational European healthcare policy
would not be able to be effectively implemented. As my research has shown, there are a number
of variables and current events that stand in the way of a cross-border healthcare policy, which I
will discuss in detail. However, let us first isolate the healthcare question, and look specifically at
this issue before considering those other variables.
Looking at Healthcare
Currently, there is effectively no legislation concerning cross-national healthcare in the
EU. The legislation that does exist only guarantees treatment to EU nationals in other memberstates, but leaves terms concerning treatment quality and cost vague. The existing framework is
extremely bare-bone, and could stand to benefit from new legislation. As mentioned earlier, the
notion of primary and secondary law in the European Union is quite important. One of the
greatest issues concerning a cross-border healthcare policy is that there is effectively no primary
law that can lead to any such policy. For that reason, any sort of directive (or other form of
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secondary law) would have no legal basis to improve the issue. The obvious implication is that
cross-border healthcare reform would require a new piece of EU primary law to come about.
When looking back at EU primary law, particularly what is stated in the Treaty of Amsterdam,
the intentions of the European Union become somewhat difficult to follow. The EU frequently
mentions human rights, and implies the need to care for every person within EU borders.
However, treaties such as Amsterdam establish very little effective law concerning healthcare,
which is an issue of upmost importance when thinking towards human rights. More specifically,
when looking at the Treaty of the Functioning of the European Union, there is only one article
(number 168) that seems relevant to cross-border healthcare. Article 168 says, “a high level of
human health protection shall be ensured in the definition and implementation of all Union
policies and activities,” and mentions that it is the duty of the EU to promote cooperation
concerning this issue among member-states (The European Union, 2012). However, Article 168
says relatively little about how cooperation among member-states in this area can be fostered, as
well as what sort of enforcement power the EU has. Another directive, approved in 2011 (also
referred to as 2011/24/EU), mentioned some more stringent rules concerning the provisions
established in Article 168 (The European Union, 2011).
Chapter 2 discussed the limited role that EU policies play in the realm of cross-border
healthcare. My findings indicated that there is little effective EU guidance in terms of how crossborder healthcare should be governed or dispatched; the Union simply stipulates a few financial
provisions. Furthermore, my research showed that these financial provisions were bureaucratic
and prone to problems of operationalization; they do not necessarily make it easy for an EU
citizen to get reimbursed for healthcare services acquired outside of their home country. Recall
my earlier example of a Dutch HIV/AIDS patient receiving care in Cyprus. Out- of-pocket
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healthcare expenditures are much higher in Cyprus than in the Netherlands (which could
potentially be correlated with better treatment quality in Cyprus), but would leave that Dutch
patient in a difficult situation in terms of being reimbursed for health costs. This all dates back to
the primary law (which is essentially the Treaty of Amsterdam), as well as the later 2011
directive addressing the issue. That directive, 2011/24/EU, states that EU member-states have an
“obligation to reimburse costs of cross- border healthcare,” but that this reimbursement should be
“limited to healthcare to which the insured person is entitled” (The European Union, 2011). A
later report from the European Commission discusses some practical difficulties with the
implementation of 2011/24/EU. The report mentions that several member-states, as of 2015, still
have not enacted reforms based on the directive, and that there continues to be ongoing litigation
with respect to this issue (The European Commission, 2015). However, the greatest difficulty
found by the European Commission concerning this directive seems to be that “the number of
citizens who are aware of their general rights to [healthcare] reimbursement is extremely low”
(European Commission, 13, 2015). Raising public awareness about this directive and patient
rights in addition to putting more pressure on member-states to adopt reforms based on EU
legislation may help to improve the cross-border healthcare situation. However, other issues
remain. Directive 2011/24/EU does little to change the status quo established by the primary law.
Medical procedures in one member-state may call for an HIV/AIDS patient to see a doctor more
frequently, or to take a different set of medications than they normally would in their home
country. The result of this could be the patient not being able to be fully reimbursed by their
home country upon returning, due to the fact that the treatment they received in the other
member-state was not consistent with the home country’s guidelines. This does little to improve
cross-border healthcare, and even without stronger primary law, this directive has limited

80

influence. However, something to point out here is that while there exists some EU primary law
concerning discrimination, there exists comparatively less with respect to healthcare. Therefore,
it is interesting to note that the 2008 proposed directive on anti-discrimination practices has not
been approved, while a 2011 directive concerning healthcare was adopted.
Stronger European Union primary law concerning healthcare across the EU is the method
by which we may see better cross-border healthcare practices. This would mean that a new treaty
would be required, but the effects that it would have on HIV/AIDS patients, as well as other
individuals suffering from chronic illnesses living with the EU could be immense. If a strong
primary law guaranteeing treatment equality across the EU is established, then HIV/AIDS
treatment across the continent should become much more harmonized. As my research indicated,
there are countries in the EU (like Germany) where healthcare systems function comparatively
better than elsewhere in the Union. This is especially true if the 2008 proposed directive, or
another strong anti-discrimination legislation, becomes adopted as well. In an ideal scenario, the
creation of strong EU primary law governing cross-border healthcare practices would ultimately
help those living with HIV/AIDS. However, as I mentioned, there are many other variables at
play. Implementation and the difficulty of creating and approving new primary law are the first
things that come to mind. However, there are other compounding factors in addition to this
(although they might initially seem less relevant), which may be some of the most pressing in
terms of the future of cross-border care, and HIV/AIDS treatment in the European Union.
Considering Other Variables
At the present moment it would be extremely difficult for cross-border legislation on
something as substantial as procedural healthcare reform (or any other form of primary law for
that matter) to be approved by member-state governments, but my results indicated a number of
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reasons for this: waning EU-support, the European economic crisis, and the European migrant
crisis. The latter of these three have a strong influence on the first; however, each of these issues
define what is happening in the modern European Union, which affects far more than just
healthcare policy.
The European monetary crisis has been extensively studied, and nearly every
commentator has added his or her viewpoint on what will happen next. The crisis began in 2008
and hit Southern Europe the hardest, but nonetheless the situation has gradually begun to
improve since then. This crisis is still very much ongoing, particularly with respect to Greece,
but the European Union has thus far managed to maintain support and manage the fallout.
Nonetheless, this is a crisis that has heavily preoccupied the governments of countries
participating in the European Monetary Union (EMU), which constitute the bulk of EU memberstates, and can be seen as a potential cause for the rise of Euroscepticism and the European far
right. At a time when the future of the strongest example of supranational power in Europe (the
EMU) is in jeopardy, it is not altogether surprising that EU politicians have refrained from
greater integration in other areas. One of the classic notions that define politics of the European
Union is that of a “two-level game”. Politicians might seek to improve things such as crossborder healthcare for HIV/AIDS patients, which is something one can see in the existing
healthcare and anti-discrimination policies of the EU. However, if advocating for such a position
will cause them to lose votes at home they have little incentive to do so. The same is true with
respect to the more recent, and arguably far more serious, European migrant crisis and the effect
that it has on the future of HIV/AIDS and healthcare in the European Union.
The European migrant crisis has affected each member-state of the European Union, and
has damaged EU approval ratings across the continent. Much like the financial crisis, once the
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migrant crisis began, no end could be seen. Millions of refugees have been pouring into Europe
from Africa and the Middle East, having initially arrived in countries bordering these regions,
such as Italy. The European Union’s inability to create an effective policy to regulate the flow of
migrants, as well as to effectively distribute refugees across member-states, has caused much
internal division in the EU. As a result, support for the European Union has shown a sharp
decrease, and many European voters have flocked to far right political parties. In seemingly
every member-state of the EU, there is a right-wing political party that wants their country to
leave the European Union, and is strongly against accepting migrants. The popularity of these
parties has increased in recent years, which adds pressure to that “two-level game” that European
politicians must play. The need for European governments to focus their attention on addressing
the migrant issue takes the attention of national governments away from topics like HIV/AIDS
morbidity and healthcare inequality.
Furthermore, the failure of the European Union to effectively address the migrant crisis
leaves some with doubts as to how effective this international organization really is. The migrant
crisis has shown policymakers just how divided different European nations are about core issues,
such as how many immigrants to allow in, and what benefits to give them. The weakness that the
EU has demonstrated with respect to the migrant crisis implies that something that requires much
deeper integration, such as procedural healthcare reform, would run in to the same conflicts of
interest that potential solutions to the migrant and financial crises have. With that said, one must
also acknowledge that both of these crises are on-going crises, and it may be that new, effective,
and supranational solutions to these dilemmas lie just ahead on the horizon. In short, it cannot be
said that a supranational European healthcare program will fail, simply because the EU has so far
been unable to develop effect solutions to these crises. However, the present situation does
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suggest that if Europe is to take action on procedural healthcare reform, the time is certainly not
now.
More so than these two crises, and also as a result of them, poor public support for the
European Union continues to be one of the largest obstacles to a common EU healthcare policy
being developed. Many Europeans are apathetic about the EU, and tend to focus more on
national politics. However, it seems that nowadays with the emergence of far right and
Eurosceptic political parties in Europe, European citizens may become less apathetic and more
opposed to the EU. The notion of a “two-level game” is perhaps the most critical aspect to take
into account when analyzing any sort of EU policy or initiative. There is simply no incentive for
a politician to be voted out of office in their home country at the price of advocating for an
unpopular supranational policy. One of the best examples of this is the relatively recent
emergence of a far-left political party in Greece, which can largely be attributed to their
predecessor giving more concessions to the European Union than what many Greeks would have
wanted. With public support for the European Union being the way it is right now, it seems
unlikely that any sort of pan-European initiative, which does not deal with the two previously
mentioned crises, will emerge anytime soon. It can also be argued that falling support for the EU
has been compounded by recent events such as the 2015 killings in Paris and 2016 attacks in
Brussels. These attacks, and other instances of violence in Europe, have helped to kick-up
islamophobia and anti-immigrant sentiments. The European Union’s decision to continue letting
migrants in can be the cause of great political upheaval, and will likely benefit the Eurosceptic
far right in coming elections. As mentioned earlier, another potential solution to improving
healthcare and the quality of life of HIV/AIDS patients is to develop and implement a stronger
European policy that targets discrimination. Such a legislative change will undoubtedly be easier
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to implement than reworking entire healthcare systems; however, with popular support being
largely pitted against the EU, this is a policy reform that may need to wait as well. At the present
moment, it may be that the European Union is about to face another impending crisis: the
success of far right parties to influence their governments to move away from supranationalism.
At a time when Euroscepticism is as strong as it has become, it may be wise for the EU to avoid
implementing a policy change or directive that could make European citizens feel that their
national governments are subservient to the European Union; and thus draw more voters to favor
nationalistic solutions instead of European cooperation.
Is a Strong Anti-Discrimination Policy the eventual way Forward?
If present anti-European sentiments are set aside, attacking the issue of discrimination in
Europe may be the best step forward for practical and effective supranational healthcare reform,
and would benefit HIV/AIDS patients in particular. Increasing anti-discrimination measures
across the European Union in theory should be far simpler and more feasible to conduct than
large healthcare reform. While the 2008 directive would not give the European Union the
strongest of tools to address the discrimination issue, it would effectively build upon previous
European legislation. The Treaty of Amsterdam is somewhat weak in terms of discrimination,
and gave the EU effectively little practical power to step in when there is a case of
discrimination, which is something the 2008 directive would do a decent job of correcting.
Nonetheless, that directive (which is currently only a proposal) would give the European Union
comparatively little power to address discrimination than what it otherwise potentially could. If
the EU were given the authority to levy fines or other similar punitive measures against national
governments that do not effectively enforce anti-discrimination policy, the result for HIV/AIDS
patients would be substantial. As was seen in the British case, laws and regulations played an
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important role in helping HIV/AIDS patients seek treatment for their disease, as well as feel safe
within their community. In Italy I saw the complete opposite, where a lack of effective
enforcement of anti-discrimination procedures has created an extremely difficult living situation
for HIV/AIDS patients in that country when coupled with the current process of healthcare
devolution that Italy is presently undergoing. Another finding to make note of is that wherever I
saw strong and effective anti-discrimination legislation, I also tended to see a larger presence of
support organizations for groups such as HIV/AIDS patients. In Italy, I saw poor antidiscrimination measures and a very weak support network, while I saw the absolute opposite in
Britain. Additionally the German case fell between Italy and the United Kingdom in terms of
both anti-discrimination measures and support groups. This is simply an observed correlation,
however, it is an area that requires more investigation in the future, should a stronger
supranational anti-discrimination policy attempt to be created.
One aspect that suggests reforming anti-discrimination policy would be more effective
than proposing procedural healthcare is ease of implementation. Adjusting to a new legal
framework, ratifying treaties, and effectively managing that “two-level game” is by no means
easy; however, it is much simpler than what the alternative would call for. Aside from all of the
major issues concerned with implementing supranational healthcare reform that I have discussed,
inequality across the European Union is possibly the biggest obstacle to such reform. There is no
doubt that different policies and procedures, even those that are supposed to be uniform, tend to
show a lot of variation among European countries. The best example of this is probably that of
the European Monetary Union (EMU). The EMU called for a universal currency to be adopted in
the EU, along with stringent guidelines concerning public debt and fiscal policy. However,
implementation of these provisions was anything but uniform across the EU. Portugal, Italy,
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Greece, and Spain took a very different attitude to public debt and spending than what was the
case in countries such as Finland and Germany. The result, also due in part to several other
factors, was the ensuing European monetary crisis.
One must remember that there is always variance between how something looks in
theory, and how it works in practice. The EMU, while by no means a failure, did not consider
many cultural and situational factors. Supranational cross border healthcare policy would likely
be more difficult to effectively implement than the EMU was, and given the country-specific
characteristics and variances that I have seen as a result of the European monetary crisis, it
would be naïve to assume that procedural healthcare reform would not become a victim of these
same pitfalls. If a stronger cross-border anti-discrimination policy can provide an effective
mechanism by which HIV/AIDS patients can enjoy a better life in Europe, then the relative ease
by which such a policy could be implemented should be taken into consideration. Creating and
enforcing new anti-discrimination measures would evolve extensive legislative action, and
would have to be implemented with respect to that “two-level game”. Nonetheless, the relative
ease and potential effectiveness of this in comparison to the alternative cannot be ignored.
Another aspect that makes this type of legislative reform seem like the more practical
solution is that despite the growing wave of Euroscepticism discussed, this type of reform would
be much less substantial than the procedural healthcare reform, and would likely not garner as
much opposition from the European far right as the former alternative would. However, that is
not to say that such supranational legal reform by the European Union will not be met with
resistance, or that it should be pursed before the two current crises that the EU is facing are
resolved. Given the present situation in Europe as discussed earlier, stronger anti-discrimination
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legislation seems like the most effective way to achieve practical change in terms of healthcare
for HIV/AIDS patients.
Looking Forward
The initial hypothesis for my study was that strong public spending and a common
European healthcare policy may lead to greater equality in European healthcare, as well as
improve the lives of those living with chronic conditions such as HIV/AIDS patients. In short,
the results of my study showed evidence against that hypothesis. From the evidence studied in
the United Kingdom, Germany, and Italy all findings suggest that these are all very different
healthcare systems, that reforming them would be extremely difficult, and that such change
would probably do more harm than good. In summary, my study did produce evidence
suggesting that a stronger European anti-discrimination law would be more feasible and effective
than healthcare reform, especially with respect to HIV/AIDS patients. My study also indicated
that one of the biggest obstacles to any sort of supranational European policy, whether that be
healthcare or otherwise, is waning support for the EU.
The primary consideration that my study offers for future research is that a closer look at
anti-discrimination laws and practices in the European Union is needed. Furthermore, extensive
research into the rise of the far right in Europe is necessary as well. Keeping in mind the two
crises that the European Union is currently undergoing, it may be that citizens turn in greater
numbers to these parties due to their alternative strategies on tackling those crises. The
importance of this with respect to the future of the European Union, as well as any future
European supranational policy, must be acknowledged. Should the far right continue to rise and
win elections, it may be that the European Union will face yet another crisis of member-states
opting to exit the organization.
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There are of course many variables that play into whether or not changes in healthcare
practices and a better life for HIV/AIDS patients in Europe will emerge in the EU. Nonetheless,
the influence of the far right in European politics is the most important finding that of my study
that should be emphasized. For the short term, it seems that any sort of major supranational
policy in Europe would not be feasible. However, that is not to say that in the coming years this
will change. In addition to examining the role and feasibility of implementing a stronger EU antidiscrimination policy, timeframe is a very important variable for further research to consider. It
may be that Europe is ultimately destined for more and more supranational reform, and that the
emergence of the far right is just a bump on the road for European integration. If things in
Europe improve over the next decade, support for the EU rises, and the need for European
healthcare overhaul emerges, then the question of supranational healthcare should again be
examined. It may be that in the coming years, Europe will once again be ready and willing to
undergo an extensive and carefully planned supranational reform, just like it did with the
European Monetary Union after the fall of communism in Europe, and that we might once again
see the expansion of the EU.
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